

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 21/00	A2	(11) International Publication Number: WO 94/01446 (43) International Publication Date: 20 January 1994 (20.01.94)
(21) International Application Number: PCT/US93/06214 (22) International Filing Date: 29 June 1993 (29.06.93) (30) Priority data: 07/910,223 9 July 1992 (09.07.92) US (71) Applicant: BECKMAN INSTRUMENTS, INC. [US/US]; 2500 Harbor Boulevard, Fullerton, CA 92634 (US). (72) Inventors: REDDY, Parameswara, M. ; 219 Valverde Ave- nue, Brea, CA 92621 (US). MICHAEL, Maged, A. ; 348 Lavender Lane, Placentia, CA 92670 (US). (74) Agent: MAY, William, H.; Beckman Instruments, Inc., 2500 Harbor Boulevard, Fullerton, CA 92634 (US).		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: DERIVATIZED ORGANIC SOLID SUPPORT FOR NUCLEIC ACID SYNTHESIS (57) Abstract A solid-phase nucleotide synthesis intermediate useful for chemical synthesis of oligodeoxyribonucleotides and oligoribonucleotides comprises: (1) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties; (2) a nucleoside; and (3) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer. The linker can comprise at least one optionally substituted aliphatic diamine. Alternatively, the linker can comprise a polyethylene glycol moiety. Preferably, the porous polymer is a methacrylate-vinylidene polymer. The solid-phase support thus produced can be used for oligodeoxyribonucleotide synthesis by either the phosphite-triester or the phosphotriester processes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

DERIVATIZED ORGANIC SOLID SUPPORT FOR
NUCLEIC ACID SYNTHESIS

5

BACKGROUND

This invention is directed to solid phase supports for oligodeoxyribonucleotide and oligoribonucleotide synthesis and methods for their use.

The ability to synthesize specific DNA and RNA sequences quickly and easily has had an impact on molecular biology unmatched by few other techniques. Such synthesized sequences are frequently used for hybridization probes, linkers for gene cloning, primers for nucleic acid amplification reactions such as the polymerase chain reaction (PCR) and the ligase chain reaction (LCR), and primers for nucleic acid sequencing.

20

DNA and RNA are both long polymeric molecules comprised of monomers known as nucleotides. Each nucleotide is composed of a nitrogenous organic base, a five-carbon sugar, and a phosphate residue. The chemical combination of the base and the sugar, which can exist separately, is known as a nucleoside. In DNA, the sugar is deoxyribose, while in RNA, it is ribose, which contains one more oxygen atom. In DNA, the bases are normally adenine (A), guanine (G), cytosine (C), and thymine (T), while in RNA, the bases are normally adenine, guanine, cytosine, and uracil (U). In natural DNA and RNA, there can be thousands of nucleotide units in one polymer, known generically as a polynucleotide: polydeoxyribonucleotide for DNA and polyribonucleotide for RNA. Shorter chains of DNA and RNA can also exist, either as a result of chemical synthesis or breakdown of a larger chain. These are known generically as oligonucleotides:

35

oligodeoxyribonucleotides for DNA and oligoribonucleotides for RNA.

Natural DNA consists of two strands of
5 polydeoxyribonucleotides bound together. The strands are held
together by base pairing, so that an adenine always pairs with
a thymine, and a cytosine always pairs with a guanine.
Although RNA generally occurs as a single stranded
polyribonucleotide, it also can form double strands by the
10 same base pairing rules, with U behaving in the same way as T
in DNA. The specificity of base pairing means that synthesis
of DNA in the laboratory must be extremely accurate to be
useful, as the insertion of even one wrong base would disrupt
the structure and make the resulting product useless.

15

Oligodeoxyribonucleotide synthesis in the laboratory
is typically carried out by one of two reaction sequences:
the phosphotriester approach and the phosphite triester
approach. The general reaction sequences are described in
20 "Oligonucleotide Synthesis: A Practical Approach," M.J. Gait,
ed., IRL Press, Oxford, 1984, incorporated herein by this
reference. In either case, the reaction sequence starts with
a 5'-protected nucleoside bound to a solid-phase support
through the 3'-carbon of the sugar. After removal of the
25 protecting group from the 5'-protected nucleoside, a 5'-OH
moiety is available for reaction with the 3'-position of
either a phosphotriester or a phosphite triester activated
nucleoside (also referred to as "activated intermediates").

30

The solid support plays a crucial role in the
success of either reaction scheme. The solid support must not
interfere with or contaminate the reaction and must make the
nucleosides attached to it available for reaction with the
activated intermediates. The choice of solid support is

important in the maintenance of a high repetitive yield, which is an important factor in the efficient synthesis of relatively long oligodeoxyribonucleotides.

5 Currently, a widely-used solid support is the inorganic material controlled pore glass (CPG). The use of this support is described in U.S. Patent No. 4,458,066 to Caruthers et al., incorporated herein by this reference. Although CPG has proven useful, it has some drawbacks. CPG
10 does not permit high levels of nucleotide loading and can be responsible for spurious indications of coupling yields. Additionally, CPG is susceptible to degradation by reagents used in the deprotection step of synthesis, such as concentrated ammonia and trichloroacetic acid, and this can
15 lead to contamination of the product. Finally, CPG can support chain growth on its surface at sites other than those associated with the 5'-terminus of an attached nucleotide and thus give rise to extraneous protected products.

20 Because of these drawbacks, in some applications it may be desirable to use an organic support. The use of an organic support would be desirable in order to provide a support compatible with a wide variety of commercially available nucleotide synthesis apparatus while providing
25 efficient synthesis at lower cost than can be obtained with CPG. It would additionally be desirable for the user to be able to attach a variety of spacers of different yet defined length for optimal performance of the synthesis.

30 However, despite this recognized need, previously-used organic supports for solid-phase nucleotide synthesis have not proven adequate for a variety of reasons including slow diffusion rates of activated nucleotides into the support, excessive swelling of the support, irreversible

absorption of reagents onto the support, low nucleotide loading, and poor repetitive yields.

Therefore, there is a need for an improved organic support for solid-phase nucleotide synthesis that can provide superior nucleotide loading, high repetitive yields, stability with commonly-used nucleotide synthesis apparatus, at a cost lower than presently-available supports.

10

SUMMARY

We have invented novel supports for oligonucleotide synthesis that meet these needs. With the invention thereof, processes for producing such supports and methods for the synthesis of nucleic acids have also been invented.

In general, a solid-phase support, according to the present invention, referred to as a "nucleotide synthesis intermediate," comprises:

- (1) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties;
- (2) a nucleoside; and
- (3) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 4 atoms away from the polymer.

Preferably, the nucleoside is a protected deoxyribonucleoside.

Preferably, the porous polymer is a methacrylate-vinylidene copolymer.

35






In a preferred embodiment, the linker comprises at least one aliphatic diamine. Each aliphatic diamine optionally contains up to 2 heteroatoms replacing carbon atoms and selected from the group consisting of O and N. The heteroatoms are bonded solely to carbon and are separated from the terminal amino group of the diamine by at least one carbon atom. The aliphatic diamines have a total chain length of from about 3 to about 36 atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups.


If the linker comprises at least one aliphatic diamine, it can be attached to the porous polymer by a carbamate moiety at one end of the diamine. The nucleoside is then linked to the other end of the diamine, preferably by a succinyl ester group.

Alternatively, a linker comprising at least one aliphatic diamine can be linked attached to the porous polymer by the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)-\text{CH}_2-$. In this structure, the first amino group of the diamine moiety attached to the particulate support is substituted with an acetyl group.

As another alternative, the linker can comprise a polyethylene glycol moiety containing from about 3 to about 10 ethylene glycol monomers, preferably from about 4 to about 7 ethylene glycol monomers. In this alternative, the polyethylene glycol moiety has a first end and a second end, with the first end covalently attached to the particulate support, and the second end terminating in an amine moiety. The nucleoside is linked to the amine moiety at the second end of the polyethylene glycol linker by an amide linkage between the amine moiety and a carboxyl group in covalent linkage with the nucleoside.

Particular nucleotide synthesis intermediates according to the present invention include those shown below as Formulas I-VI. In these formulas, (F) is a macroreticular methacrylate-vinylidene polymer, X is a nucleoside, and Z is a 5'-protecting group.





10 A process of producing nucleotide synthesis intermediates according to the invention comprises generally:

(1) coupling:

(a) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties, with:

15 (b) a linker having a first and a second end, the first end being covalently attached to the particulate support; and

(2) coupling the second end of the linker to a nucleoside, the linker spacing the nucleoside at least 4 atoms away from the polymer.

25 Nucleotide synthesis intermediates according to the present invention can be used for nucleotide synthesis in either the phosphite-triester or the phosphotriester synthesis method.

30 In general, the phosphite-triester method for synthesis of DNA, used with solid supports according to the present invention, comprises the steps of selecting a solid-phase intermediate containing a 5'-protected deoxyribonucleoside, removing the protecting group, coupling the free 5'-OH group with a phosphoramidite, oxidizing the phosphite triester linkage to a phosphotriester linkage,

acetylating unreacted 5'-OH groups, and cleaving the synthesized oligonucleotide from the solid support.

5 In general, the phosphotriester method for synthesis of DNA, used with solid supports according to the present invention, comprises the steps of selecting a solid-phase intermediate containing a 5'-protected deoxyribonucleoside, removing the protecting group, coupling a phosphorylated nucleotide to form a dinucleotide, and cleaving the
10 synthesized oligonucleotide from the solid support.

Nucleotide synthesis intermediates according to the present invention are capable of supporting efficient synthesis of nucleotides up to at least 1000 bases in length.
15

BRIEF DESCRIPTION OF THE DRAWINGS

20 These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description, appended claims, and the accompanying drawings where:

Figure 1 is a capillary gel electropherogram of a 24-base oligodeoxyribonucleotide synthesized using controlled
25 pore glass;

Figure 2 is a capillary gel electropherogram of the same 24-base oligodeoxyribonucleotide synthesized using a solid support according to the present invention;

Figure 3 is a capillary gel electropherogram of the
30 same 24-base oligodeoxyribonucleotide synthesized using a different solid support according to the present invention;

Figure 4 is a capillary gel electropherogram of a 35-base oligodeoxyribonucleotide synthesized using controlled pore glass;

Figure 5 is a capillary gel electropherogram of the same 35-base oligodeoxyribonucleotide synthesized using a solid support according to the present invention;

5 Figure 6 is a capillary gel electropherogram of the same 35-base oligodeoxyribonucleotide synthesized using a different solid support according to the present invention;

Figure 7 is a capillary gel electropherogram of the same 35-base oligodeoxyribonucleotide synthesized using another different support according to the present invention;

10 Figure 8 is a capillary gel electropherogram of the same 35-base oligodeoxyribonucleotide synthesized using another different support according to the present invention;

Figure 9 is a slab gel electropherogram of 24- and 35-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using
15 different nucleotide synthesis apparatuses;

Figure 10 is a slab gel electropherogram of 35-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different
20 nucleotide synthesis apparatuses;

Figure 11 is a slab gel electropherogram of 35- and 51-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses;

25 Figure 12 is a slab gel electropherogram of 51-, 70-, and 101-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses;

30 Figure 13 is a slab gel electropherogram of 24- and 35-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses, showing different syntheses than depicted in Figure 11;

Figure 14 is a slab gel electropherogram of 35-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses, showing different syntheses than depicted in Figure 10;

Figure 15 is a slab gel electropherogram of 51-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses, showing different syntheses than depicted in Figures 10 and 14;

Figure 16 is a slab gel electropherogram of 51-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention, using different nucleotide synthesis apparatuses;

Figure 17 is a slab gel electropherogram of 101-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention;

Figure 18 is a slab gel electropherogram of 35-, 70-, and 101-base oligodeoxyribonucleotides synthesized with different solid supports according to the present invention;

Figure 19 is a slab gel electropherogram of products from a polymerase chain reaction synthesis using a 17-base oligodeoxyribonucleotide produced with a solid support according to the present invention as a primer; and

Figure 20 is a gel showing the result of a chain-terminating DNA sequencing reaction performed on the products from the polymerase chain reaction synthesis.

DEFINITIONS

Definitions for a number of terms that are used in the following Descriptions, Examples, and appended claims are collected here for convenience.

"Polymer": A polymer is a molecule comprised of a number of individual monomer units chemically linked together. The individual monomer units can be the same or different. A polymer whose individual monomer units are carbon-containing is an organic polymer, while a polymer whose individual monomer units do not contain carbon is an inorganic polymer.

"Partially Hydrophilic": A polymer is partially hydrophilic when at least about 25% of the exposed individual monomer units can interact with water.

"Polar": A solvent is polar when it can mix with water and has molecules which are polarized to produce partial positive and negative electrical charges at opposite ends of the molecule.

"Aprotic": A solvent is aprotic when it has no proton that can be removed by the action of a base in an aqueous solution.

"Optionally Substituted": A polymer or other molecule is optionally substituted when it can contain substituent groups in place of hydrogen atoms on the polymer. When this term is used, both the molecule without the substituent groups and the molecule with the substituent groups are included. The optional substituents are of a type that do not alter the overall chemical reactivity of the polymer or other molecule.

"Aliphatic": An aliphatic molecule is an organic molecule whose backbone contains carbon and hydrogen with no carbon-carbon double bonds or triple bonds.

"Diamine": An organic molecule containing two amine (-NH₂) groups, typically at opposite ends of the chain. As used herein, the term "diamine" includes derivatives of aliphatic diamines optionally containing up to 2 heteroatoms. In such derivatives, the heteroatoms replace carbon atoms.

"Porous": A polymer is porous when it contains pores that can be penetrated by a solvent into which the polymer is placed.

"Mean Diameter": The arithmetic average of the diameters of an assemblage of particles.

"Monoderivatized": A molecule is monoderivatized when it contains one substituent of a particular type, as distinguished from two or more substituents.

"Acylating": Reacting an alcohol or amino group with a reagent containing an acyl (RCO-) group. A common example of acylation is acetylation, in which R is methyl (CH₃).

"Capping": A process for ensuring that hydroxy (-OH) residues remaining on a polymer are blocked, typically by forming an ester linkage.

"Spacer" or "Linker": These terms, used interchangeably, both refer to a portion of a composite structure that spatially separates a reactive molecule from a large polymer so that reagents can react readily with the reactive molecule without interference from the polymer.

"Activated Nucleoside": A nucleoside one of whose 3'- or 5'- positions is substituted with a group that can

react to form a bond with another nucleoside is known as "activated." Typically, an activated nucleoside incorporates an acid group such as an ester function.

5 "3'-Protected" and "5'-Protected": Because the 3'- and 5'-positions of the sugar residue of the nucleotide are involved in the formation of the phosphodiester bonds, each nucleotide to be added must be protected on one of these groups to ensure that only the correct position of the sugar
10 residue reacts to form the phosphodiester bond.

"Exocyclic Amino Protecting Group": Certain of the bases of the nucleotides, in particular adenine, guanine, and cytosine, have amino groups whose reactivity could interfere
15 with oligodeoxyribonucleotide synthesis. These amino groups must be blocked or protected, typically by acylation. The group used for protection is referred to as an exocyclic amino protecting group.

20 "Nucleotide Synthesis Intermediate": A substituted polymer according to the present invention incorporating an activated nucleotide and suitable for oligonucleotide synthesis is designated a nucleotide synthesis intermediate.

25

DESCRIPTION

 We have discovered that a number of organic polymers not based on dextran or other carbohydrate polymers are useful
30 as solid supports for solid-phase oligodeoxyribonucleotide synthesis.

I. THE POLYMERS

The polymers useful for synthesis according to the present invention are porous organic polymers, at least partially hydrophilic and having hydroxy residues, whose backbone comprises optionally substituted acrylate or methacrylate moieties. Preferably, the backbone comprises straight-chain acrylate or methacrylate moieties. The optional substitutions can include any groups that do not significantly react with any of the other reagents employed for coupling or subsequent DNA synthesis, such as 1,1'-carbonyldiimidazole or oxidizing agents. Such groups include, but are not limited to, aryl groups, alkoxy groups, and heterocyclic groups. The polymers are substantially free of pyranose or furanose moieties or their derivatives.

Specific and preferred polymers that fall within the description include, but are not limited to:

- (1) Macroreticulated methacrylate-vinylidene copolymers available from Tosohaas (Philadelphia, Pennsylvania) under the name of TOYOPEARL™ and from Merck (Darmstadt, Germany) under the name of FRACTOGEL™, described by U.S. Patents Nos. 4,224,415; 4,256,840; 4,297,220; and 4,501,816 to Meitzner et al., all of which are incorporated herein by this reference;
- (2) Homopolymers of pentaerythritol dimethacrylate, described generally in U.S. Patent No. 4,246,362 to Sasaki et al., incorporated herein by this reference;
- (3) Copolymers of pentaerythritol dimethacrylate and a methacrylate monomer, described by U.S. Patent No. 4,246,362 to Sasaki et al., supra;
- (4) Copolymers of a hydrophilic monomer selected from the group consisting of hydroxyalkyl methacrylates, aminoalkyl methacrylates, N-vinylpyrrolidone, acrylonitrile,

methacrylonitrile, acrylic acid, methacrylic acid, and mixtures thereof, with a substantially hydrophobic monomer selected from the group consisting of ethylene dimethacrylate, ethylene diacrylate, methylenebisacrylamide, diethylene glycol methacrylamide, poly (ethyleneglycol) methacrylamide, neopentyl glycol diacrylate, neopentyl glycol dimethacrylate, trimethylol propane trimethacrylate, divinylbenzene, and mixtures thereof, described generally in U.S. Patent No. 4,184,020 to Lim et al., incorporated herein by this reference;

(5) Copolymers of polar monomers such as hydroxyalkyl acrylates and hydroxalkyl methacrylates, with non-polar monomers such as alkyl acrylates and methacrylates, together with cross-linking agents such as alkylene diacrylates and methacrylates, described generally in U.S. Patent No. 4,135,892 to Coupek et al., incorporated herein by this reference; and

(6) Polymers comprising the reaction product of:

(a) a hydroxyalkyl or aminoalkyl acrylate or methacrylate, and acrylamide or methacrylamide;

(b) an alkylene diacrylate or dimethacrylate, or an acrylate or methacrylate of a polyalcohol, a dihydroxy or polyhydroxy ether, an alkylene bisacrylamide, or divinylbenzene; and

(c) acrylanilide, methacrylanilide, phenyl acrylate, phenyl methacrylate, phenoxyalkyl acrylate, phenoxyalkyl methacrylate, or styrene, with the aromatic ring being chloromethylated, as described generally in U.S. Patent No. 3,925,267 to Coupek et al, incorporated herein by this reference.

Preferred organic polymers are the macroreticulated methacrylate-vinylidene copolymers.

As described below, in a particularly preferred embodiment, the polymers are either extended with alkanediamine spacers or derivatized with polyethylene glycol to provide a framework for attachment of the protected deoxyribonucleoside. Alternatively, it is also possible to directly attach the protected deoxyribonucleoside to the hydroxy groups of the polymer.

In general, the nucleotide synthesis intermediate produced by this process comprises:

- (1) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties;
- (2) a nucleoside; and
- (3) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the protected deoxyribonucleoside at least 4 atoms away from the polymer.

20

In this structure, the linker is used to separate the first nucleoside from the support, so that the nucleoside is reactive to form a bond with a second nucleoside, thus beginning the process of oligonucleotide synthesis.

25

II. PROCESS FOR PRODUCING A DERIVATIZED SOLID-PHASE SUPPORT

The organic polymers defined and disclosed herein can be used in a process for producing a particulate porous organic solid-phase support derivatized with, e.g., a protected deoxyribonucleoside.

30

Generally, this process involves: (1) attaching one end of the spacer to the polymer; (2) attaching the nucleoside

35

to the other end of the spacer so that the nucleoside is separated from the polymer by the spacer; and (3) blocking any reactive groups on the polymer that might interfere with subsequent nucleotide synthesis reactions.

5

A. Support with Alkanediamine Spacer

One version of the process results in a support incorporating an alkanediamine spacer.

10

In general, this process comprises the steps of:

(1) coupling:

(a) a porous solid-phase particulate support comprising a porous polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties, the porous polymer being extended with a linear polymer having first and second ends, the linear polymer being covalently linked through the first end to the porous polymer, the linear polymer comprising at least one aliphatic diamine, the linear polymer having an amino group at its second end, with:

(b) a nucleoside, such that the nucleoside is covalently linked to the amino group at the second end of the linear polymer;

25

(2) acylating terminal amino groups remaining uncoupled; and

(3) blocking hydroxy residues on the solid phase support.

30

Each aliphatic diamine can optionally contain up to 2 heteroatoms replacing carbon atoms. The heteroatoms are selected from the group consisting of oxygen and nitrogen. The heteroatoms are bonded solely to carbon and are separated

from the terminal amino group of the diamine by at least one carbon atom.

5 The aliphatic diamines have a total chain length of from about 3 to about 36 carbon atoms. If more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups.

10 In general, the nucleotide synthesis intermediate produced by this process comprises:

15 (1) a porous solid-phase particulate support comprising a porous organic polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties;

20 (2) a linear polymer having first and second ends, the linear polymer being covalently linked through the first end to the particulate support, the linear polymer comprising at least one aliphatic diamine as described above, the linear polymer having an amino group at its second end available for reaction with an activated protected deoxyribonucleoside, the linkage between the particulate support and the first end of the linear polymer comprising a carbamate moiety; and

25 (3) a nucleoside linked to the second end of the linear polymer.

1. The Condensation Step

This step involves the condensation or coupling of at least one alkanediamine moiety to the polymer to produce a polymer extended with a spacer or linker. The spacer or linker is subsequently coupled to a nucleoside, resulting in the nucleotide synthesis intermediate.

(a) Preferred Polymers

10

Preferred polymers for assembly of the solid-phase support are the macroreticulated methacrylate-vinylidene copolymers TOYOPEARL™ (available from Tosohaas) and as FRACTOGEL™ (available from Merck). Particularly preferred polymers are such methacrylate-vinylidene copolymers having particles of from about 5 microns to about 200 microns in mean diameter, preferably from about 30 microns to about 70 microns; most preferred are particles having a mean diameter of about 45 microns. These values are mean values, and individual particles vary somewhat in size.

These preferred polymers can have a range of porosities; most preferred are polymers having pores of a size that excludes proteins of molecular weight greater than 5×10^6 . Also particularly preferred are polymers having pores of a size that excludes proteins of a molecular weight greater than about 5×10^7 .

(b) Diamines

30

As used herein, the term "diamine" includes derivatives of aliphatic diamines optionally containing up to 2 heteroatoms. In such derivatives, the heteroatoms replace carbon atoms. The heteroatoms are selected from the group

consisting of oxygen and nitrogen. The heteroatoms are bonded solely to carbon and are separated from the terminal amino group of the diamine by at least one carbon atom.

5 The diamines can be either straight-chain or branched-chain. Preferably, the diamines are straight-chain.

 The diamine linker can have a total chain length, counting only methylene ($-\text{CH}_2-$) groups and heteroatoms
10 substituting for carbon and not amino or carbonyl groups, of from 3 to 36 atoms, more preferably 6 to 18 carbon atoms. Each diamine moiety preferably has a chain length of from 3 to 12 atoms. If there is more than one diamine moiety, the diamine moieties can have the same or different chain lengths.
15 If branched-chain diamines are included, the chain length intended is the longest continuous chain present.

 Particularly preferred diamine arrangements are the following:

- 20 (1) One diamine moiety of six carbon atoms;
 (2) One diamine moiety of 12 carbon atoms;
 (3) Two diamine moieties of six carbon atoms each;
 and
 (4) Three diamine moieties of six carbon atoms
25 each.

(c) Reaction Conditions

 The coupling reaction is preferably performed in a
30 polar, aprotic solvent such as acetonitrile. The polymer to be derivatized is suspended in the solvent at a concentration of from about 0.05-0.2 g/ml of solvent. Preferably the polymer is suspended at about 0.1 g/ml of solvent. The coupling reaction is performed using a coupling agent.

Preferably, the coupling agent is 1,1'-carbonyldiimidazole, and is used at a concentration of about 1.0 mole/l. Other coupling agents, such as carbodiimides, are also well known in the art.

5

The coupling reaction results in the coupling of some of the hydroxy residues of the polymer to diamines. The hydroxy residues not coupled to diamines are blocked, as described below, to prevent interference with the remaining reactions.

10

Accordingly, the first stage in a preferred coupling reaction is the reaction of 1,1'-carbonyldiimidazole, at a concentration of about 1.0 mole/l, with the polymer suspended in acetonitrile at about 0.1 g/ml. This reaction occurs at a temperature of about 15°-30°C, preferably at room temperature. Preferably, the reaction is allowed to proceed from about 2-6 hours, more preferably for about 4 hours. After this reaction is substantially complete, the polymer can be used for coupling to a diamine.

15

20

The first alkanediamine to be coupled to the polymer is then added to the reaction mixture to a concentration of about 0.5-2 mole/l, preferably at about 1.0 mole/l. The reaction is allowed to occur overnight.

25

Subsequent to the coupling of the alkanediamine to the polymer, the remaining hydroxy-containing sites on the polymer are blocked by the addition of a quantity of an aliphatic monoamine sufficient to react with all remaining activated hydroxyl groups. Preferably, the aliphatic monoamine is selected from the group consisting of ethylamine, n-propylamine, n-butylamine, and piperidine. Most preferably, the aliphatic monoamine is n-propylamine. Most preferably,

30

the blocking reaction is carried out prior to the coupling of additional alkanediamine residues, if any.

5 If more alkanediamine residues are to be coupled to the polymer, the blocked, monoderivatized polymer is suspended in a halogen-containing solvent such as dichloromethane. The coupling reagent p-nitrophenylchloroformate is then added to a concentration of about 0.5-2 mole/l, preferably about 1 mole/l. Then a methylated pyridine derivative, serving as a
10 base, is added to a concentration of about 0.5 to about 3.0 moles/l, preferably about 1.5 moles/l. Preferably, the methylated pyridine derivative is collidine. The reaction of the monoderivatized polymer is allowed to occur overnight at a temperature between about 15°C and 30°C, preferably room
15 temperature.

Alternatively, a second alkanediamine residue can be added by means of reaction with carbonyldiimidazole. The monoderivatized solid support is suspended in dry
20 acetonitrile, 1,1'-carbonyldiimidazole is added to a concentration of 0.5 mole/l to about 1.5 mole/l, preferably about 1.0 mole/l, and the reaction allowed to proceed at a temperature of 15°-30°C, preferably room temperature, for a reaction time of about 2 hours to about 6 hours, preferably
25 about 4 hours.

The support is then filtered and washed with acetonitrile, and then resuspended in that solvent. The second alkanediamine to be coupled is added at a concentration
30 of about 0.5 mole/l to about 1.5 mole/l, preferably about 1.0 mole/l, and the mixture shaken overnight. The diderivatized support is washed extensively. A preferable washing routine is 10 times with acetonitrile, 20 times with distilled water, 3 times with acetonitrile, 3 times with dichloromethane, and

twice with ether. The support is then dried under vacuum to remove the remaining ether.

2. The Coupling Step

5

The nucleoside coupled is preferably an activated aryl ester of a protected deoxyribonucleoside. In the ester, the carboxyl function is being sufficiently activated to create a linkage between the deoxyribonucleoside and the solid support.

10

(a) The Protected Nucleoside

The process of the present invention can be used to produce nucleotide synthesis intermediates containing either a deoxyribonucleoside, for DNA synthesis, or a ribonucleoside, for RNA synthesis. Additionally, the nucleoside can be protected at either its 5'-end or its 3'-end. Typically, the nucleoside is protected at the 5'-end, for synthesis in the 3'- to 5'- direction. However, the nucleoside can also be protected at the 3'-end, for synthesis in the 5'- to 3'- direction.

15

20

Protected deoxyribonucleosides are commonly used for coupling to the solid support. Protection of both the exocyclic amino groups of adenine, cytosine, and guanine, is well understood in the art. Thymine and uracil, which have no exocyclic amino group on its base, does not require a protecting group thereon. Protection of either the 5'-hydroxyl group or 3'-hydroxyl group of all of the four common deoxyribonucleosides and the four common ribonucleosides is also well understood in the art.

25

30

Typically, the exocyclic amino groups are protected by acylation. The benzoyl group is used to protect both adenine and cytosine, while the isobutyryl group is used to protect guanine. Other alternative protecting groups are known, such as phthaloyl or di-N-butylaminomethylene for the amino group of adenine.

As those in the art appreciate, the 5'-hydroxyl or the 3'-hydroxyl group is typically protected with triphenylmethyl (trityl), 4-methoxytriphenylmethyl (methoxytrityl), or 4,4'-dimethoxytriphenylmethyl (dimethoxytrityl). The dimethoxytrityl protecting group is generally preferred.

Preferably, the protected deoxyribonucleoside used in the coupling reaction is protected at the 5'-hydroxyl group.

(b) The Coupling Reaction

The coupling of the activated aryl ester of the protected deoxyribonucleoside with the support typically occurs in two stages: (i) formation of the activated aryl ester from a carboxyl-containing derivative of the protected nucleotide; and (ii) reaction of the activated aryl ester with the amino-terminated derivatized support. Other coupling reactions are possible that result in the coupling of the protected deoxyribonucleoside to the amino terminus of the support. See, for example, M.J. Gait, "Oligonucleotide Synthesis: A Practical Approach," supra.

The activated aryl ester is preferably an ester of a succinyl or oxalyl derivative of the protected nucleoside with a phenol substituted with at least one electron-withdrawing substituent. Such a substituent activates the derivative for

reaction with an electron-rich group like a hydroxyl group. Most preferably, the activated aryl ester is a succinyl derivative and the substituted phenol is *p*-nitrophenyl. Therefore, the compound coupled is most preferably a *p*-nitrophenyl ester of a succinylated protected nucleoside.

A preferred coupling procedure is described below and sets forth in detail the coupling of the *p*-nitrophenyl ester of succinylated 5'-protected thymidine. It is to be understood that other nucleosides, including ribonucleosides, can be coupled in much the same manner; any variations are considered to be within the skill of the art.

Succinylated 5'-protected thymidine is dissolved in dioxane at a concentration of about 0.113 mole/l, containing pyridine (about 0.045% (v/v)), and *p*-nitrophenol is added at about 10:1 molar ratio to the succinylated thymidine. The coupling agent, 1,3-dicyclohexylcarbodiimide, is then added at about a 2.5:1 molar ratio to the succinylated thymidine. The coupling reaction is allowed to go to completion (typically about three hours), and dicyclohexylurea precipitates out. The supernatant, containing the *p*-nitrophenyl ester, is added to the derivatized solid support suspended in dry *N,N*-dimethylformamide (5 g support in 22 ml of dimethylformamide). Triethylamine (about 1.0 ml triethylamine per gram of derivatized support), is added, and the mixture shaken briefly. The period of time used for reaction between the *p*-nitrophenyl ester and the support, as well as the concentration of the *p*-nitrophenyl ester, can be varied to give different levels of loading the support, as shown below in Table I. The support on which the deoxyribonucleoside has been loaded is then washed, as with *N,N*-dimethylformamide (five times), methanol (five times), and ether (twice), and then dried under vacuum.

35

TABLE I

LOADING OF SOLID METHACRYLATE-VINYLDENE POLYMERIC
SUPPORT WITH ACTIVATED PROTECTED THYMIDINE

Concentration of Activated Protected Thymidine, mole/l	Reaction Time, min.	Nucleoside Loading, μ mole/g
0.2	180	70-90
0.1	30	40-50
0.05	30	25-35
0.01	30	10-15


Table I shows that the quantity of nucleoside loaded per gram of support varies with the time of reaction and the concentration of activated protected nucleoside used. The longer the time or the greater the concentration, the greater is the quantity of nucleoside loading that results.

3. The Capping Step


Preferably, the final step of the reaction is the capping of all remaining unreacted amino groups on the nucleoside-loaded solid support. Preferably, the capping is accomplished by acylation. Most preferably, the capping is performed by acetylation.

For capping by acetylation, the support is resuspended in dry pyridine (1 g support per 10 ml pyridine). N,N-dimethylaminopyridine is added to 0.2 mole/l, followed by acetic anhydride to 2.5 mole/l. The reaction mixture is shaken overnight at a temperature of 15°-30°C, preferably room temperature. The solid support is filtered and washed extensively, as with N,N-dimethylformamide (five times), acetonitrile (five times), dichloromethane (five times), and then once with ether. The derivatized, capped solid support is then dried under vacuum. The derivatized support is stable and can be stored.


The result of this process is a derivatized support, four examples of which are shown below as schematic formulas I-IV.



(I)




5



10

15



20

In these formulas, $\textcircled{\text{F}}$ represents the
 methacrylate-vinylidene porous solid support, X represents a
 nucleoside, and Z represents a 5'-protecting group for the
 nucleoside. The diagonal lines, by convention, represent
 methylene ($-\text{CH}_2-$) groups. These formulas show the blocking of
 unreacted hydroxy groups on the porous solid support by
 reaction with an amine, and the capping of remaining free
 amino groups (either from the blocking reaction or from the
 linker) by acetylation.

30

The support can be prepared with any DNA or RNA base
 attached to the support: adenine, thymine, guanine, or

cytosine for DNA, and uracil instead of thymine in the case of RNA.

5 The quantity of protected nucleoside derivatized per
gram of solid support ranges from about 5 $\mu\text{mole/g}$ to about 200
 $\mu\text{mole/g}$. Typically, the quantity is about 30 $\mu\text{mole/g}$. As
shown above in Table I, the level of loading of nucleoside can
be varied by varying the time of reaction of the p-nitrophenyl
10 ester with the support and varying the concentration of p-
nitrophenyl ester used for reaction.

 The fully derivatized support is thoroughly washed
and filtered, then dried. Several different washing regimes
are possible. For support derivatized by one alkanediamine,
15 the support can be washed five times with dichloromethane, ten
times with acetone, five times with acetonitrile, and five
times again with dichloromethane. The last dichloromethane
filtrate is then tested qualitatively for amino groups using
the ninhydrin test, in which a positive result (i.e., the
20 presence of amino groups) yields a blue color and a negative
result yields no color. The ninhydrin test should be negative.
The support is then washed twice with ether and dried under
vacuum, preferably about five hours. For a support
derivatized with two alkanediamine moieties, the solid support
25 can be washed with dichloromethane and then 95% ethanol. The
filtrates can be collected and assayed by absorbance at 402
nanometers (A_{402}) for determining p-nitrophenol, which is a
measure of the quantity of amino groups attached to the
support. Other washing schemes are possible, as long as they
30 substantially remove unreacted reagents.

B. Support with Polyethylene Glycol Linker

Another version of the process results in a support incorporating a polyethylene glycol linker.

5

In general, this process preferably comprises the steps of:

(1) coupling:

10 (a) a porous solid-phase support comprising a methacrylate-vinylidene copolymer extended with polyethylene glycol, the polyethylene glycol having from about 2 to about 20 ethylene glycol moieties and containing a terminal amino group, with:

15 (b) a nucleoside covalently linked to the terminal amino group through an amide linkage; and

(2) acylating terminal amino groups that are not coupled to nucleosides.

20 Preferably, the nucleoside is a protected deoxyribonucleoside.

This results in the nucleoside being linked to the terminal amino group of the polyethylene glycol-derivatized polymer. Accordingly, the nucleotide synthesis intermediate produced thereby comprises:

25 (1) a porous solid-phase particulate support comprising a methacrylate-vinylidene copolymer;

30 (2) a polyethylene glycol linker having from about 2 to about 20 ethylene glycol moieties and having a first end and a second end, the first end covalently attached to the particulate support, the second end terminating in an amine moiety; and

(3) a nucleoside linked to the amine moiety at the second end of the polyethylene glycol linker by an amide

linkage between the amine moiety and a carboxyl group in covalent linkage with the nucleoside.

5 The length of the polyethylene glycol linker is preferably from about 3 to about 10 monomers, most preferably from about 4 to about 7 monomers.

10 Typically, the particles of the porous particulate support are from about 10 microns to about 200 microns in mean diameter; preferably from about 30 microns to about 70 microns; most preferably, they are about 60 microns in mean diameter.

15 1. The Coupling Reaction

The coupling reaction between the activated aryl ester of the protected deoxyribonucleoside and the solid support occurs in two stages, as described above in Section II(A) (2).

20 In a preferred embodiment, in which the activated aryl ester is a p-nitrophenyl ester and the deoxyribonucleoside is succinylated, the formation of the p-nitrophenyl ester of the succinylated protected
25 deoxyribonucleoside is described in Section II(A) (2), supra.


30 The p-nitrophenyl ester is reacted with the amino-derivatized support by the following procedure: The support is suspended in dry N,N-dimethylformamide. The p-nitrophenyl ester is added as a supernatant from the coupling procedure, and triethylamine is added (1 ml per 2 ml dimethylformamide). The reaction mixture is shaken at a temperature between about 15°C and about 30°C for about 15

minutes to about one hour. Preferably, the reaction is performed at room temperature for about 30 minutes.

The solid support on which the deoxyribonucleoside has been loaded is then filtered and successively washed with N,N-dimethylformamide (three times), methanol (two times), and ether (two times), and dried under vacuum.

2. The Acetylation Reaction (Capping Step)

The acetylation reaction is performed as detailed in Section II(A) (2), supra, in dry pyridine, with the addition of N,N-dimethylaminopyridine and acetic anhydride. The acetylated support is washed successively with N,N-dimethylformamide, acetonitrile, and dichloromethane, and dried under vacuum. The derivatized solid support produced by this method has the schematic structure shown below as Formula V.



C. Support Derivatized with Epichlorohydrin

Another version of the process first reacts the support with epichlorohydrin (1-chloro-2,3 epoxypropane), and then reacts the epoxy function of the epichlorohydrin with an alkanediamine.

In general, this version of the process comprises the steps of:

(1) condensing a porous solid-phase particulate support comprising a porous polymer as described above, with epichlorohydrin;

(2) condensing:

5 (a) the reaction product between the polymer and epichlorohydrin with:

(b) at least one aliphatic diamine as described above, to form a modified solid phase support containing at least one diamine linked to the solid support by
10 a spacer with the structure $-O-CH_2-CHOH-CH_2-$, the modified solid phase support having a terminal amino group available for reaction with a nucleoside;

(3) reacting the modified solid phase support with a short-chain alkylamine;

15 (4) coupling the terminal amino group of the solid phase support with a nucleoside; and

(5) acetylating terminal amino groups remaining uncoupled.

20 Preferably, the nucleoside is a protected deoxyribonucleoside

The nucleotide synthesis intermediate thus produced comprises:

(1) a porous solid-phase particulate support
25 comprising a porous organic polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties;

(b) a linear polymer having first and second ends,
30 the linear polymer being covalently linked through the first end to the particulate support, the linear polymer comprising at least one aliphatic diamine as described above, the aliphatic diamines having a total chain length of from about 6 to about 36 carbon atoms, the linkage between the particulate

support and the first end of the linear polymer comprising a spacer with the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)-\text{CH}_2-$, with the first amino group of the diamine moiety attached to the particulate support being substituted with an acetyl group; and

- 5 (3) a nucleoside linked to the second end of the linear polymer.

The linear polymer that links the particulate support and the nucleoside has an amino group at its second
10 end available for reaction with the nucleoside. If more than one diamine is present in the linear polymer, the diamines are linked to each other by carbonyl groups.

Preferably, only one diamine is used. Most
15 preferably, the single diamine has a chain length of twelve carbon atoms.

1. The Reaction With Epichlorohydrin

20 (a) Preferred Polymers

Preferred polymers in this version are the same as those described above (Section II(A)(I)(a), supra). A methacrylate-vinylidene copolymer that is particularly
25 preferred has a mean particle diameter of about 45 microns. This polymer has pores of a size that exclude proteins of molecular weight greater than about 5×10^6 .

(b) Reaction Conditions

30

The hydroxy-terminated polymer is slightly moistened with a small amount of water and suspended in a 1.5 N-2.5 N solution of alkali metal hydroxide. Preferably the concentration of alkali metal hydroxide is about 2 N and the

alkali metal hydroxide is sodium hydroxide. Epichlorohydrin is added to a final concentration of from about 2.4 mole/l to about 2.7 mole/l; preferably, the concentration of epichlorohydrin is about 2.56 mole/l. The mixture is shaken
5 for about 2-4 hours, preferably about 3 hours. The epichlorohydrin-derivatized solid support is filtered and washed with distilled water until the washes have a neutral pH.

10 2. Condensation Reaction

The epichlorohydrin-derivatized polymer is subsequently condensed with an alkanediamine moiety. The epichlorohydrin-derivatized polymer is resuspended in N,N-
15 dimethylformamide, and the alkanediamine is added to a concentration of about 0.5 mole/l. The mixture is shaken overnight at a temperature from about 15°-30°C, preferably room temperature. If desired, additional alkanediamine moieties can be added as described above.

20 3. The Blocking Step

All unreacted epichlorohydrin moieties remaining on the solid support are then blocked by reaction with a short-
25 chain aliphatic primary amine. Preferably, the primary amine is n-propylamine. The blocking step is carried out as follows: The short-chain aliphatic primary amine is added to a concentration of about 1 mole/l and the reaction mixture is shaken for an additional period of about two hours.

30 Subsequently, the solid support is filtered and washed successively with, e.g., dimethylformamide (five times), acetone (five times), acetonitrile (five times),

dichloromethane (five times) and ether (two times). The support is then dried under vacuum.

4. The Coupling Step

5

The coupling step is carried out as described above in Section A. The quantity of nucleoside loading can be varied by varying the concentration of activated nucleoside and the time of reaction, as shown in Table II.

10


TABLE II

LOADING OF SOLID SUPPORT DERIVATIZED WITH
EPICHLOROHYDRIN WITH ACTIVATED
PROTECTED THYMIDINE

Concentration of Activated Protected Thymidine, mole/l	Reaction Time min.	Nucleoside Loading, μ mole/g
0.2	120	90-120
0.1	30	50- 60
0.05	30	40- 50
0.02	30	25- 35
0.005	30	10- 15

5. The Capping Step

The final step of the process is a capping step, in which all remaining unreacted amino groups and hydroxyl groups are capped by acetylation. This is carried out as described above in Section II(A) (2), supra. After acetylation, the support is filtered and washed successively with N,N-dimethylformamide, acetonitrile, dichloroethane (five times each), then twice with ether, and dried under vacuum for about five hours. The resulting derivatized support has the structure shown below in Formula VI. In Formula VI, Ac represents acetyl (-COCH₃).



20 III. USE OF THE SOLID SUPPORTS IN OLIGODEOXYRIBONUCLEOTIDE SYNTHESIS

The solid-phase supports of the present invention are particularly suitable for use with either the phosphite-triester or the phosphotriester method of oligonucleotide synthesis.

In general, and with respect to the 3' to 5' synthesis of deoxyribonucleotides on a solid support, the phosphite-triester method comprises the steps of:

- 30 (1) selecting a suitable solid-phase nucleotide synthesis intermediate prepared as described above, the nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;

(2) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by treating the intermediate with acid to yield a free 5'-OH group;

5 (3) coupling the free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage between the 5'-carbon of the deoxyribonucleoside attached to the solid support and the deoxyribonucleoside residue of the phosphoramidite;

10 (4) oxidizing the phosphite triester linkage to a phosphotriester linkage to yield a dinucleotide attached to the solid support;

(5) acetylating remaining unreacted 5'-OH groups after the coupling steps;

15 (6) repeating, for each additional nucleotide residue added to the chain, the steps of removing the protecting group, coupling the resulting free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage, oxidizing the phosphite linkage to a phosphotriester linkage, and acetylating
20 remaining unreacted 5'-OH groups; and

(7) cleaving the oligodeoxyribonucleotide from the solid support.

25 In general, and with respect to the 3' to 5' synthesis of deoxyribonucleotides on a solid support, the phosphotriester method comprises the steps of:

(1) selecting a suitable solid-phase nucleotide synthesis intermediate prepared as described above, the
30 nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;

(2) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by

treating the intermediate with acid to yield a free 5'-OH group;

5 (3) coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside having a protected 5'-OH group in the presence of a coupling agent and catalyst to form a dinucleotide attached to the solid support;

(4) optionally, acetylating remaining unreacted 5'-OH groups after the coupling steps;

10 (5) repeating, for each additional nucleotide residue added to the chain, the steps of removing the protecting group, coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside, and optionally, acetylating 5'-OH groups remaining unreacted; and

15 (6) cleaving the completed oligodeoxyribonucleotide from the solid support.

In this procedure, the coupling agent is preferably 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole and the catalyst 1-methylimidazole.

20

The phosphite-triester and phosphotriester procedures are well known in the art and are described in Gait, supra.

25

Solid supports according to the present invention can be used for synthesis in automated equipment, including, but not limited to, the Gene Assembler™ (Pharmacia, Uppsala, Sweden), the Biosearch™ 8750 (Milligen Biosearch, San Rafael, California), and the ABI PCR Mate™ (ABI, Foster City, California). The use of automated equipment is well known in the art of oligodeoxyribonucleotide synthesis. Solid supports, according to the present invention, can be used to synthesize oligodeoxyribonucleotides up to at least 1000 residues in length.

35

The following Examples are for illustrative purposes only and are not to be construed as limiting the scope of the invention, or the claims to follow, in any manner.

5

EXAMPLESExample 1

10

Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Diaminododecane
Spacer Coupled to Thymidine

15

FRACTOGEL™-65F (Tosohaas, Philadelphia, Pennsylvania) (10 g, dry weight) was suspended in 100 ml of dry acetonitrile. The condensing agent 1,1'-carbonyldiimidazole (16.2 g, to make a solution of 1 mole/l), was added and the reaction mixture was shaken at room temperature for four hours. The solid support was filtered on a sintered glass funnel and washed four times with 100 ml of dry acetonitrile each time. The solid support was then resuspended in 100 ml of dry dichloromethane.

20

The spacer, 1,12-diaminododecane (20 g, to make a solution of 1 mole/l) was added and the reaction mixture was shaken at room temperature overnight (i.e., for 16-20 hours). The blocking agent n-propylamine (8.2 ml, to make a solution of 1 mole/l) was added to the above mixture. The mixture was then shaken for an additional hour.

25

30

The support was filtered and washed successively five times with 100 ml each time of dichloromethane, ten times with 100 ml each time of acetone, five times with 100 ml each time of acetonitrile, and five times with 100 ml each time of dichloromethane. After the last of the dichloromethane

washes, the filtrate was tested qualitatively by reaction with ninhydrin. The support was then washed twice with 100 ml each time of ether. The support was dried under vacuum for about five hours.

5

A qualitative ninhydrin test was performed for monitoring amino groups on the solid support. For the ninhydrin test, Reagent 1 was 0.01 mole/l aqueous KCN (2 ml) diluted to 100 ml with pyridine. Reagent 2 was a 5% ninhydrin solution in *n*-butanol. Reagent 3 was 80% phenol in *n*-butanol. An aliquot (about 3-5 mg) of the solid support was placed in a test tube and equal amounts (about 5 drops each) of Reagents 1, 2, and 3 were successively added. The test tube was placed in a preheated block at 100°C for 5 minutes. The beads gave a dark blue color, which indicated a positive amine reaction.

15

Additionally, the amino groups on the solid support were quantitated by a quantitative picric acid test. The reagents used were Reagent A, 5% (v/v) diisopropylethylamine in dichloromethane; and Reagent B, 0.1 mole/l picric acid in dichloromethane. An accurately weighed amount of the solid support (5-10 mg) was placed in a small column fitted with a Teflon™ stopcock. The solid support was washed twice with 2 ml each of dichloromethane and then treated twice with 2 ml of Reagent A for one minute each. The support was then washed five times with 1 ml each of dichloromethane for one minute each time. The solid support was then treated twice with Reagent B, 2 ml each time, for one minute each time. The support was washed five times with dichloromethane, 1 ml each time, for one minute each time. The picrate was eluted twice with Reagent A (2 ml each time, 1 minute each). The picrate was diluted with 95% ethanol to give an absorbance measurable at 358 nm in the spectrophotometer. The amino group content

25

30

on the solid support was calculated using the following formula:

$$\text{Amino groups } (\mu\text{mole/g}) = \frac{A_{358} \times V \times 1000}{14.5 \times W}$$

In this formula, A_{358} is the measured absorbance at 358 nm, V is the volume of the solution in milliliters, $E \times 10^{-3}$ is 14.5, and W is the weight of the sample used in the test in milligrams.

The amino group content on the solid support was typically 300-400 $\mu\text{mole/g}$.

15 The next step in the preparation of the derivatized
solid support was loading the amino-containing solid support
with 5'-dimethoxytrityl-thymidine. Different concentrations
of the 5'-dimethoxytrityl-thymidine succinates were prepared
according to the required nucleoside loading. The particular
20 procedure set forth here was used for preparing a 0.05 mole/l
solution to load 5 g of the solid support.

The succinylated 5'-dimethoxytrityl-thymidine (2.5 mmole) was dissolved in 22 ml of dry dioxane containing 1 ml of dry pyridine and 350 mg of p-nitrophenol (25 nmole). The condensing agent (1,3-dicyclohexylcarbodiimide; 1.29 g, 6.25 mmole) was then added. After a few minutes dicyclohexylurea began to precipitate. The reaction mixture was shaken at room temperature for three hours. The dicyclohexylurea was then removed by filtration and the supernatant was added to the amino-derivatized solid support (5 g) suspended in dry N,N-dimethylformamide (22 ml).

Triethylamine (5 ml) was added to the above mixture
35 and the mixture was shaken briefly by hand. A bright yellow

color developed, due to the release of p-nitrophenol. The reaction was shaken for a period of time sufficient to give the required nucleoside loading. (See Table I above).

5 The supernatant was removed and used to derivatize another aliquot (2-3 g) of amino-derivatized solid support because it still contained activated deoxyribonucleoside.

10 The deoxyribonucleoside-derivatized solid support was washed extensively: 5 times with 100 ml each of N,N-dimethylformamide, 5 times with 100 ml each of methanol, and twice with 100 ml each of ether. The solid support was then dried under vacuum.

15 The remaining amino groups on the deoxyribonucleoside-loaded solid support were then capped by acetylation. The solid support (5 g) from the previous step was suspended in 50 ml of dry pyridine. N,N-dimethylaminopyridine (1.25 g, to make an 0.2 mole/l solution)
20 was added followed by the addition of acetic anhydride (12.5 ml, to make a solution of 2.5 mole/l). The mixture was shaken at room temperature overnight.

25 The solid support was filtered and washed successively with 5 x 50 ml each of N,N-dimethylformamide, acetonitrile, and dichloromethane, and once with ether. The support was then dried under vacuum for about 5 hours. The amine-capped solid support was tested by the ninhydrin test
30 for complete capping. The test showed that there were no free (i.e., uncapped) amino groups remaining on the solid support.

Example 2Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Diaminododecane Spacer Coupled
To Deoxycytidine

5

A solid support derivatized with a diaminododecane spacer coupled to deoxycytidine was prepared as in Example 1, except that the protected deoxyribonucleoside used was benzoyl-dimethoxytrityl-deoxycytidine succinate. This protected and activated deoxycytidine derivative was substituted for dimethoxytrityl-thymidine succinate used in Example 1.

10

Example 3Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Diaminododecane Spacer Coupled
To Deoxyguanosine

15

A solid support derivatized with a diaminododecane spacer coupled to deoxyguanosine was prepared as in Example 1, except that isobutyryl-dimethoxytrityl-deoxyguanosine succinate was substituted for dimethoxytrityl-thymidine succinate, as used in Example 1.

20

25

Example 4Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Diaminododecane Spacer Coupled
To Deoxyadenosine

30

A solid support derivatized with a diaminododecane spacer coupled to deoxyadenosine was prepared as in Example 1, except that benzoyl-dimethoxytrityl-deoxyadenosine succinate was substituted for dimethoxytrityl-thymidine succinate, as used in Example 1.

35

The nucleoside loading on the solid supports for Examples 1-4 was determined using two methods. The first method was quantitating the released dimethoxytrityl color. The second was by quantitating the released nucleoside. The released nucleoside was quantitated by determining its ultraviolet absorption.

For the first method, an accurately weighed amount (428 mg) of the solid support was placed in a disposable column of 5 ml capacity. A solution of dichloroacetic acid (2.5% in dichloromethane) was added to the solid support (about 1 ml) and shaken for one minute, and then filtered into a measuring cylinder. Another 1-ml portion was added, shaken for one minute, and filtered into the same cylinder. The volume was brought to 10 ml with the same dichloroacetic acid solution. The optical density was measured at 500 nm using the dichloroacetic acid solution as a blank. The nucleoside loading was estimated from the DMT assay using the following formula:

20

$$DMT = \frac{A_{500} \times V \times 1000}{80 \times W}$$

where A_{500} is the measured absorbance at 500 nanometers, V is the volume in milliliters of dichloroacetic acid solution used, 80 is the molar absorbance times 1×10^{-3} of DMT at 500 nm, and W is the weight in mg of the solid support.

For the second method, nucleoside release, the solid support from step two of the first method was washed with 5 ml of dichloromethane and 5 ml of acetonitrile, and then dried. The solid support was treated with 1 ml of ammonia at room temperature for one hour to bring about hydrolysis of the 3'-succinate bond. The ammonia solution was transferred to a screw-cap vial, capped tightly, and sealed well with parafilm.

The vial containing the nucleoside was placed in a water bath at 65°C for three hours. The vial was cooled before opening, left open at room temperature for at least 30 minutes, and then evaporated to dryness using a vacuum concentrator. The residue was dissolved in 1 ml of double distilled water. The ultraviolet absorbance was read at the following wavelengths: 264 nm for thymidine; 260 nm for deoxyadenosine; 269 nm for deoxycytidine; and 255 nm for deoxyguanosine. Nucleoside loading was determined according to the following formula:

$$\text{Nucleoside loading} = \frac{A \times 1000}{E \times W}$$

where E is the extinction coefficient for the particular deoxyribonucleoside in $\mu\text{mole/ml}$; 15.26 for deoxyadenosine; 7.70 for deoxycytidine; 11.50 for deoxyguanosine; and 8.83 for thymidine), and W is the weight of the solid support in mg.

The values obtained for loading by the two methods are shown below in Table III. As can be seen, there is substantial agreement between the two methods.

TABLE III
NUCLEOSIDE LOADING FOR EXAMPLES 1-4

Nucleoside Loaded	Loading Determined by DMT Release, $\mu\text{mole/g}$	Loading Determined by Nucleoside Release, $\mu\text{mole/g}$
T (Ex. 1)	29.96	28.10
A (Ex. 2)	34.70	34.20
C (Ex. 3)	36.50	34.41
G (Ex. 4)	35.90	35.90

Example 5Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Polyethylene Glycol
Linker Coupled to Thymidine

5

To prepare a solid support derivatized with a polyethylene glycol linker coupled to thymidine, FRACTOGEL™-65M (AF-amino-650M, Tosohaas, Philadelphia, Pennsylvania) was used. This macroreticular methacrylate-vinylidene copolymer
10 has amino-terminated polyethylene glycol residues attached thereto.

Succinylated dimethoxytrityl-thymidine (3.23 mg, 0.5 mmole) was dissolved in 4 ml of dry dioxane containing 0.2 ml
15 of dry pyridine and 70 mg of p-nitrophenol (0.5 mmole). The coupling agent 1,3-dicyclohexylcarbodiimide (259 mg, 1.25 mmol) was then added. After a few minutes dicyclohexylurea began to precipitate. The reaction mixture was shaken at room temperature for three hours. The dicyclohexylurea was removed
20 by filtration and the supernatant was added to the amino-derivatized methacrylate-vinylidene copolymer (1 g, amino groups = 400 µmole/g) suspended in 4 ml of dry N,N-dimethylformamide.

25 Triethylamine (2 ml) was added to the above reaction mixture. The reaction mixture was shaken at room temperature for 30 minutes.

The solid support was filtered and successively
30 washed with N,N-dimethylformamide (3 times with 10 ml each), methanol (twice with 10 ml each), and ether (twice with 10 ml each), and dried under vacuum for about five hours. In order to cap the remaining amino groups on the nucleoside-loaded solid support by acetylation, the solid support from the

previous step (1 g) was suspended in 10 ml of dry pyridine. N,N-dimethylaminopyridine (250 mg, to make a solution of 0.2 mole/l) was added followed by 2.5 ml of acetic anhydride (to make a 2.5 mole/l solution). The reaction mixture was shaken
5 at room temperature overnight. The solid support was filtered and washed successively with N,N-dimethylformamide, acetonitrile, and dichloromethane (5 times with 10 ml of each solvent), and then twice with ether (10 ml each time) and dried under vacuum for about five hours.

10

The solid support was tested for complete capping by the ninhydrin test. A negative result was obtained, (i.e., no blue color), indicating that there were no free amino groups remaining. The nucleoside loading on the solid support was
15 estimated by quantitating the released DMT color as described in Example 1. The nucleoside loading was determined to be 28 μ mole/g.

Example 6

20

Synthesis of Macroreticular Methacrylate-Vinylidene Copolymer Derivatized With Two Diaminohexane Spacers Joined By Carbonyl Linkage and Coupled To Thymidine

A procedure similar to that disclosed in Example 5
25 was used to couple two diaminohexane residues to an hydroxyl-terminated macroreticular methacrylate-vinylidene copolymer.

FRACTOGEL™-65F (10 g dry weight) was suspended in 100 ml of dry acetonitrile. The coupling agent, 1,1'-
30 carbonyldiimidazole (16 g, to make a solution of 1 mole/l) was added and the reaction mixture was shaken at room temperature for four hours. The solid support was filtered on a sintered glass funnel and washed four times with 100 ml each time of dry acetonitrile.

35

The washed solid support was then resuspended in 100 ml of dry acetonitrile. The first diaminohexane spacer was coupled by adding 11.6 g of 1,6-diaminohexane to make a 1 mole/l solution. The mixture was shaken at room temperature overnight. Next, 8.2 ml *n*-propylamine (to make 1 mole/l) was added. The mixture was then shaken for an additional hour. The solid support was then filtered and washed successively ten times with 100 ml each time of acetonitrile, twenty times with 100 ml each time of distilled water, three times with 100 ml each time of acetonitrile, three times with 100 ml each time of dichloromethane, and twice with 100 ml each time of ether. The solid support was then dried under vacuum for about five hours. A picric acid assay showed an amino group loading of about 500-600 μ mole/g.

15

To add a second diaminohexane moiety to the solid support, 10 g of the solid support was suspended in 100 ml of dry acetonitrile. The coupling agent 1,1'-carbonyldiimidazole (16.2 g to make a solution of 1 mole/l) was added, and the mixture was shaken at room temperature for four hours. The solid support was then filtered and washed five times with 100 ml each of dry acetonitrile and resuspended in 100 ml of dry acetonitrile. The second diamine moiety, 1,6-diaminohexane, was added (11.6 g to make a solution of 1 mole/l). The mixture was then shaken at room temperature overnight. The solid support was then filtered and washed successively ten times with 100 ml each of acetonitrile, twenty times with 100 ml each of distilled water, three times with 100 ml each of acetonitrile, three times with 100 ml each of dichloromethane, and twice with 100 ml each with ether. The solid support was then dried under a vacuum for about five hours. The picric acid assay showed that the amino group loading was about 350-400 μ mole/g.

30

The next step was the loading of the amino-terminated solid support with thymidine. Succinylated 5'-dimethoxytrityl-thymidine (1.61 g, 2.5 mmole) was dissolved in 22 ml of dry dioxane containing 1 ml of dry pyridine and 330 mg of p-nitrophenol (2.5 mmole). The condensing agent, 1,3-dicyclohexylcarbodiimide (1.29 g, 6.25 mmole) was then added. After a few minutes, dicyclohexylurea began to precipitate. The reaction mixture was shaken at room temperature for 3 hours. The dicyclohexylurea was removed by filtration and the supernatant was added to the amino-derivatized solid support (5 g) suspended in 22 ml of dry N,N-dimethylformamide. Triethylamine (5 ml) was added to the above reaction mixture, which was then shaken briefly by hand. A bright yellow color developed due to the release of p-nitrophenol. The reaction mixture was then shaken at room temperature for thirty minutes. The solid support was then filtered and successively washed five times with 100 ml each time of N,N-dimethylformamide, five times with 100 ml each time of methanol, and twice with 100 ml each of ether, and then dried under vacuum for about five hours.

The next step was the capping of the remaining amino groups on the nucleoside-loaded solid support by acetylation. The solid support from the previous step (5 g) was suspended in 50 ml of dry pyridine. N,N-dimethylaminopyridine (1.25 g, to make a 0.2 mole/l solution) was added followed by 12.5 ml of acetic anhydride (to make a 2.5 mole/l solution). The reaction mixture was shaken overnight at room temperature. The solid support was filtered and washed successively five times with 50 ml each time of N,N-dimethylformamide, acetonitrile, and dichloromethane, and then with 250 ml of ether. The support was then dried under a vacuum for about 5 hours. The amino-capped solid support was tested by the ninhydrin test for complete capping, which gave a negative

result. The nucleoside loading on the solid support was estimated by quantitating the released dimethoxytrityl color; the nucleoside loading was determined to be 39 $\mu\text{mole/g}$.

5

Example 7

Synthesis of Macroreticular Methacrylate-Vinylidene
Copolymer Derivatized With Two Diaminohexane Spacers
Joined By Carbonyl Groups and Coupled To Thymidine,
With Second Diaminohexane Spacer Coupled by
Reaction With p-Nitrophenylchloroformate

10

The solid support, FRACTOGEL™-75F (exclusion limit 5×10^7 molecular weight for proteins; particle size 30-60 microns) (1 g dry weight) was suspended in 20 ml of dry acetonitrile. The coupling agent 1,1'-carbonyldiimidazole (3.24 g, to make a solution of 1 mole/l) was added and the mixture was shaken at room temperature for four hours. The solid support was filtered on a sintered glass funnel and washed five times with dry acetonitrile (10 ml each time).

20

The solid support was then resuspended in 20 ml of dry acetonitrile. The first diamine moiety, 1,6-diaminohexane (2.32 g, to make a solution of 1 mole/l) was added and the mixture shaken at room temperature overnight. The blocking agent n-propylamine (1.64 ml) was added to the above mixture. The mixture was then shaken for an additional hour. The solid support was filtered and washed successively ten times with 10 ml of acetonitrile each time, twenty times with 10 ml of distilled water each time, three times with 10 ml of acetonitrile each time, three times with 10 ml of dichloromethane each time, and twice with 10 ml of ether each time. The solid support was then dried under a vacuum for about five hours. The picrate assay showed that amino group loading was about 250-270 $\mu\text{mole/g}$.

35

To add a second diaminohexane moiety, the solid support (1 g) was suspended in 20 ml of dry dichloromethane. The coupling agent *p*-nitrophenylchloroformate (4.02 g, to make a solution of 1 mole/l) was added, followed by addition of
5 3.95 ml collidine (to make a 1.5 mole/l solution). The mixture was then shaken at room temperature overnight.

The solid support was then filtered and washed five times with dry dichloromethane (20 ml each time) and
10 resuspended in 20 ml of dry dichloromethane. The second diamine moiety, 1,6-diaminohexane (2.32 g, to make a solution of 1 mole/l) was added, followed by 3.03 ml triethylamine, to make a 1.5 mole/l solution, and the mixture shaken at room temperature overnight. The solid support was filtered and
15 washed twice with 10 ml each time of dichloromethane and five times with 10 ml each time of 95% ethanol. The filtrates were collected and brought up to 50 ml with 95% ethanol to be used for the *p*-nitrophenol assay, as described below. The solid support was further washed five times with methanol (10 ml
20 each time), five times with acetonitrile (10 ml each time), five times with dichloromethane (10 ml each time), and twice with 10 ml each time of ether. The support was dried under vacuum for about five hours.

25 For the *p*-nitrophenol assay, the *p*-nitrophenol-diaminohexane salt solution obtained from the above reaction was appropriately diluted and read for absorbance at 402 nm. The amount of *p*-nitrophenol released in the reaction, which corresponds to the amount of amino groups attached, was
30 calculated from the formula:

$$\text{Nitrophenol release } (\mu\text{mole/g}) = \frac{A_{402} \times V \times 1000}{21 \times W}$$

5 where A_{402} is the absorbance at 402 nm, V is the final volume in milliliters of the solution used to measure the absorbance, 21 is the extinction coefficient $\times 10^{-3}$ of the p-nitrophenol amine complex at 402 nm, and W is the weight of the solid support in grams.

10 The assay indicated that the amount of p-nitrophenol released was 200 to 240 $\mu\text{mole/g}$. By the picrate acid assay, the amino group loading was 190 to 240 $\mu\text{mole/g}$.

15 The next step was the loading of the amino-terminated solid support with thymidine. Succinylated 5'-dimethoxytrityl-thymidine (1.29 g, 2 mmole) was dissolved in 4 ml of dry dioxane containing 0.4 ml of dry pyridine and 280 mg of p-nitrophenol (2 mmole). The coupling agent 1,3-dicyclohexylcarbodiimide (1.30 g, 5 mmole) was then added.
20 After a few minutes, dicyclohexylurea began to precipitate. The reaction mixture was shaken at room temperature for 3 hours.

25 The dicyclohexylurea was removed by filtration and the supernatant was added to the amino-derivatized solid support (1 g) suspended in 4 ml of dry N,N-dimethylformamide. Triethylamine (2 ml) was added to the above reaction mixture. The reaction mixture was then shaken at room temperature overnight.

30 The solid support was then filtered and successively washed 3 times with 10 ml each time of N,N-dimethylformamide, twice with 10 ml each time of methanol, and twice with 10 ml each time of ether. The solid support was then dried under
35 vacuum for about 5 hours.

The final step was the capping of the remaining amino groups on the nucleoside-loaded solid support by acetylation. The solid support (1 g) from the previous step was suspended in 10 ml of dry pyridine. N,N-
5 dimethylaminopyridine (250 mg, to make a solution of 0.2 mole/l) was added, followed by the addition of 2.5 ml acetic anhydride (to make a solution of 2.5 mole/l). The reaction mixture was shaken at room temperature overnight. The solid support was then filtered and washed successively 5 times with
10 10 ml each time with the following reagents: N,N-dimethylformamide, acetonitrile, and dichloromethane. The solid support was then washed twice with 10 ml each time of ether and then dried under vacuum for about 5 hours.

15 The nucleoside loading on the solid support was 28 to 30 μ mole/g, estimated by quantitating the released DMT color.

Example 8

Synthesis of Macroreticular Methacrylate-Vinylidene 20 Copolymer Derivatized with Epichlorohydrin and Diaminododecane and Coupled to Thymidine

The solid support, FRACTOGEL™-65F (10 g), slightly
25 moistened with a small amount of water (about 5 ml), was suspended in 2 N aqueous sodium hydroxide solution (50 ml) by shaking. Epichlorohydrin (10 ml) to make a solution of 2.56 mole/l) was added and the mixture was shaken at room temperature for 3 hours.

30 The solid support was filtered and washed with distilled water in a sintered glass funnel until the washes were neutral to pH paper. The solid support (slightly wet) was resuspended in 100 ml of N,N-dimethylformamide.

35

The diamine spacer, powdered 1,12-diaminododecane (10 g, to make a solution of 0.5 mole/l) was added and the mixture was shaken at room temperature overnight (i.e., about 16 to 20 hours). The blocking agent *n*-propylamine (8.2 ml, to make a solution of 1 mole/l) was added to the above mixture. The mixture was then shaken for an additional 2 hours.

The solid support was then filtered and washed successively 5 times with 100 ml each time of *N,N*-dimethylformamide, 5 times with 100 ml each time of acetone, 5 times with 100 ml each time of acetonitrile, and 5 times with 100 ml each time of dichloromethane. The last washing with dichloromethane gave a negative ninhydrin test. Finally, the solid support was washed twice with 100 ml each time of ether and dried under vacuum for about 5 hours. The picrate acid assay showed that the amino group loading was about 700 to 800 $\mu\text{mole/g}$.

The next step was the loading of the amino-terminated solid support with thymidine. Different concentrations of the activated thymidine succinate could be used, according to the required nucleoside loading. In this example, a 0.05 mole/l reagent was prepared to load 1 g of the solid support.

For this procedure, succinylated 5'-dimethoxytrityl-thymidine (323 mg, 0.5 mmole) was dissolved in 4 ml of dry dioxane containing 0.2 ml dry pyridine and *p*-nitrophenol (70 mg, 0.5 mmole). The coupling agent 1,3-dicyclohexylcarbodiimide (258 mg, 1.25 mmole) was added and the reaction mixture was shaken at room temperature for 3 hours. The dicyclohexylurea was removed by filtration and the supernatant was added to the amino-derivatized solid support (1 g) suspended in 4 ml dry *N,N*-dimethylformamide. *N,N*-

triethylamine (2 ml) was added to the reaction mixture. The reaction mixture was shaken for an appropriate time to obtain the required loading of nucleoside.

5 The loaded solid support was then filtered and successively washed 3 times with 10 ml each time of N,N-dimethylformamide, twice with 10 ml each time of methanol, and twice with 10 ml each time of ether. It was then dried under vacuum for about 5 hours. The nucleoside loading on the solid
10 support was estimated by quantitating the released DMT color.

 The last step was the capping of the remaining amino groups on the nucleoside-loaded solid support by acetylation. The solid support (1 g) from the previous step was suspended
15 in 10 ml dry pyridine. N,N-dimethylaminopyridine (250 mg, to make a solution of 0.2 mole/l) was added followed by acetic anhydride (2.5 ml, to make a solution of 2.5 mole/l). The reaction mixture was shaken at room temperature overnight. The solid support was filtered and washed successively with 5
20 x 10 ml each time of N,N-dimethylformamide, acetonitrile, and dichloromethane, then twice with 10 ml each time of ether. The solid support was dried under vacuum for about 5 hours.

 The amino-capped solid support was tested by the
25 ninhydrin test for complete capping. The ninhydrin test gave a negative result, which indicated complete capping of the solid support.

Example 9

30 DNA Synthesis of 17-Mer Using Derivatized Solid Supports

 The following sequence, 5'-TGTAATGCCATCGACT-3' (SEQ ID NO: 1), was synthesized using the derivatized solid supports described above and several types of commercially available in vitro DNA synthesis apparatus.

35

(a) Synthesis Using Controlled Pore Glass (500 Å) (Control)
With Pharmacia Gene Assembler™

5 As a control, the DNA sequence described was
synthesized using controlled pore glass of 500 Å porosity on
the Pharmacia Gene Assembler™ DNA synthesis apparatus
(Pharmacia, Uppsala, Sweden). The normal procedure for
synthesis using this apparatus was followed as provided by the
manufacturer. The trityl coupling efficiency for the
10 synthesis is shown below in Table IV.

TABLE IV
TRITYL COUPLING EFFICIENCIES ON
PHARMACIA GENE ASSEMBLER

Solid Support of Example No.:	Length of DNA Synthesized:					
	17	24	35	51	70	101
CPG - Thymidine (Control)	99.6	99.3	99.1	98.6	98.5	99.0
1	100.0	99.9	99.1	98.9	98.7	99.1
5	NT	98.6	98.9	99.9	99.3	99.6

Table IV shows that the solid supports of Examples 1 and 5 are at least as efficient as CPG for synthesis of oligonucleotides ranging in length from 17 bases to 101 bases ("NT" means "not tested"). In particular, the solid supports of Examples 1 and 5 proved more efficient than CPG for synthesis of relatively long oligonucleotides, i.e., nucleotides of 51 bases or more. High repetitive yield is most important in synthesizing long oligonucleotides. A brief calculation shows that a repetitive yield of 99% per cycle gives a total yield of 90.4% after 10 cycles and 81.8% after 20 cycles. However, a decrease of only 1% in the repetitive yield, to 98%, gives a total yield of only 81.7% after 10 cycles and 66.8% after 20 cycles.

TABLE V

TRITYL COUPLING EFFICIENCIES ON
PHARMACIA GENE ASSEMBLER

Solid Support of Example No.:	Length of DNA Synthesized:
	35
CPG-Thymidine Control	99.1
1	99.1
2	98.6
3	98.9
4	98.8
5	98.9

Table V shows that solid supports according to the present invention can be used to synthesize deoxyribonucleotides efficiently with any of the four common DNA nucleotides attached to the solid support.

(b) Synthesis Using the Solid Support of Example 1 on the Pharmacia Gene Assembler

5 The solid support of Example 1 was similarly used for synthesis with the Pharmacia Gene Assembler. The trityl coupling efficiency is shown in Table IV above.

10 It can be seen that the solid support of Example 1 is as efficient in the synthesis of the 17-mer oligodeoxyribonucleotide as is controlled pore glass.

Example 10

DNA Synthesis of 24-Mer Using Derivatized Solid Supports

15

A 24-nucleotide DNA sequence, 5'-ATTGAGAAAGCGCCACGCTTCCCT-3' (SEQ ID NO: 2), was synthesized using derivatized solid supports as described above and in vitro DNA synthesis apparatus, also as described above.

20

(a) Synthesis Using Controlled Pore Glass (500 Å) (Control) With Pharmacia Gene Assembler

25 The 24-mer described above was synthesized using controlled pore glass of 500 Å porosity, as a control, on the Pharmacia Gene Assembler as described above. The trityl coupling efficiency for this synthesis is shown in Table IV.

30 The DNA synthesized was analyzed by capillary gel electrophoresis. The capillary gel column used was from Beckman Instruments, Fullerton, California (U100P urea gel). The electrophoresis was run on a Beckman P/ACE™ high performance capillary electrophoresis system. A 7 M urea in Tris-hydroxymethylaminomethane-HCl ("Tris-HCl") buffer was

used according to instructions. The capillary gel electropherogram for the synthesized DNA is shown in Figure 1. The results indicate that the synthesized nucleotide was substantially homogeneous.

5

(b) Synthesis Using Solid Support of Example 1 With Pharmacia Gene Assembler

10 The same oligonucleotide was synthesized using the solid support of Example 1 on the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency is shown in Table IV, and the capillary gel electropherogram is shown in Figure 2. The electropherogram showed a single sharp
15 spike. This indicates that the synthesized nucleotide was substantially homogeneous and contained fewer contaminants of differing molecular weight than the nucleotide synthesized with controlled pore glass.

20 (c) Synthesis Using Solid Support of Example 5 on Pharmacia Gene Assembler

The same oligodeoxyribonucleotide was synthesized using the solid support of Example 5 on the Pharmacia Gene Assembler. The trityl coupling efficiency is shown in Table
25 IV, above, while a capillary gel electropherogram of the synthesized DNA is shown in Figure 3.

30 (d) Synthesis Using Solid Support of Example 6 on Pharmacia Gene Assembler

The sequence was synthesized using the solid support of Example 6, above, on the Pharmacia Gene Assembler.

(e) Synthesis With Controlled Pore Glass (500 Å Porosity)
(Control) On the Biosearch Apparatus

5 The sequence described above was synthesized using controlled pore glass (500 Å) porosity on the Biosearch™ 8750 DNA synthesis apparatus (Milligen Biosearch, San Rafael, California). The manufacturer's instructions were followed.

10 Trityl coupling efficiency was determined by measuring spectrophotometrically the released trityl color after the first coupling and the n-1st coupling, and then calculating using the formula:

15 Stepwise coupling efficiency = $e^{[ln Y/(n-1)]}$ where Y is (absorbance of color released after n-1 couplings)/(absorbance of color released after the first coupling) and n is the number of nucleotides. The trityl coupling efficiency is shown in Table VI below ("NT" means "not tested").

TABLE VI

TRITYL COUPLING EFFICIENCIES FOR BIOSEARCH 8750

Solid Support of Example No.:	Length of DNA Synthesized				
	24	35	51	70	101
CPG - Thymidine (Control)	98.1	98.3	97.9	NT	NT
1	98.2	98.6	99.1	NT	NT
5	NT	98.8	NT	NT	NT
6	NT	98.5	NT	NT	NT
7	NT	98.7	98.0	98.0	98.4
8	NT	98.8	100.0	100.0	NT

(f) Synthesis Using Solid Support of Example 1 on the Biosearch Apparatus

5 The same oligodeoxyribonucleotide was also synthesized using the solid support of Example 1 on the Biosearch apparatus. The trityl coupling efficiency is shown in Table VI. The trityl coupling efficiency is substantially equivalent for the solid support of Example 1 and the controlled pore glass control.

10

(g) Synthesis Using Solid Support of Example 6 on Biosearch Apparatus

15 The same sequence was also synthesized using the solid support of Example 6 on the Biosearch apparatus. This DNA was used for other studies as described below.

Example 11

DNA Synthesis of 35-Mer Using Derivatized Solid Support

20

An oligodeoxyribonucleotide of 35 residues, 5'-GATGCCAGTTCGGTCATACACGTAGTACTACGACT-3' (SEQ ID NO: 3), was synthesized using the solid supports described above on various DNA synthesis apparatuses.

25

(a) Synthesis With Controlled Pore Glass (500 Å Porosity) (Control) on Pharmacia Gene Assembler

30 Controlled pore glass with 500 Å porosity, as a control, was used to synthesize the sequence on the Pharmacia Gene Assembler. The trityl coupling efficiency is shown in Tables IV and V. A capillary gel electropherogram of the synthesized DNA is shown in Figure 4.

(b) Synthesis Using Solid Support of Example 1 with Pharmacia Gene Assembler

5 The solid support of Example 1 was used for synthesis with the Pharmacia Gene Assembler. The trityl coupling efficiency is given in Tables IV and V. A capillary gel electropherogram of the synthesized DNA is shown in Figure 5.

10 (c) Synthesis Using Solid Support of Example 2 with Pharmacia Gene Assembler

15 The solid support of Example 2 was similarly used for synthesis with the Pharmacia Gene Assembler to synthesize the 35-nucleotide sequence described above. Because the nucleoside attached to the solid support is deoxycytidine for Example 2, the sequence actually synthesized had a C at its 3'-terminal end instead of a T. The trityl coupling efficiency for this synthesis is shown in Table V.

20

(d) Synthesis Using Solid Support of Example 3 with Pharmacia Gene Assembler

25 The same 35-residue oligodeoxyribonucleotide was synthesized using the solid support of Example 3 on the Pharmacia gene assembler. Because this solid support has a deoxyguanosine residue attached to it, the nucleotide had a G at its 3'-terminal end rather than a T. The trityl coupling efficiency for this synthesis is shown in Table V.

30

(e) Synthesis Using Solid Support of Example 4 with Pharmacia Gene Assembler

5 The solid support of Example 4 was used to synthesize the same 35-residue oligodeoxyribonucleotide. Because the solid support of Example 4 has an deoxyadenosine residue attached to the solid support, the synthesized DNA had an A at its 3'-terminus instead of a T. The trityl coupling efficiency for this synthesis is shown in Table V.

10

The results of Examples 11(a) through 11(e) indicate that the solid phase support of Example 1 can be used for synthesis with any attached deoxyribonucleoside residue.

15 (f) Synthesis Using Solid Support of Example 5 with Pharmacia Gene Assembler

20 The solid support of Example 5 was used for synthesis with the Pharmacia Gene Assembler for synthesis of the 35-residue oligodeoxyribonucleotide whose sequence is given above. (For this and all other portions of Example 11, the solid support has a thymidine residue attached, so the sequence synthesized is identical to the one set out initially at the beginning of the Example.) The trityl coupling efficiency for this synthesis is shown in Tables IV and V. A capillary gel electropherogram of the synthesized DNA is shown in Figure 6.

25

30 (g) Use of Solid Support of Example 6 For Synthesis with Pharmacia Gene Assembler

The solid support of Example 6 was used for the synthesis of the 35-residue oligodeoxyribonucleotide given

above with the Pharmacia Gene Assembler. A capillary gel electropherogram of the synthesized DNA is shown in Figure 7.

5 (h) Use of the Solid Support of Example 8 for Synthesis with the Pharmacia Gene Assembler

10 The solid support of Example 8 was similarly used with the Pharmacia Gene Assembler for synthesis of the 35-residue oligodeoxyribonucleotide. A capillary gel electropherogram of the synthesized DNA is shown in Figure 8.

(i) Use of Controlled Pore Glass (500 Å Porosity) (Control) for Synthesis with the Biosearch Synthesis Apparatus

15 Controlled pore glass of 500 Å porosity, a control, was used for synthesis of the 35-residue oligodeoxyribonucleotide described above on the Biosearch 8570 synthesis apparatus. The trityl coupling efficiency is given in Table VI.

20 (j) Use of Solid Support of Example 1 for Synthesis with Biosearch Synthesis Apparatus

25 The solid support of Example 1 was used for synthesis with the Biosearch 8750 DNA synthesis apparatus to synthesize the 35-residue oligodeoxyribonucleotide described above. The trityl coupling efficiency is shown in Table V.

30 (k) Use of Solid Support of Example 5 for Synthesis on Biosearch Synthesis Apparatus

The solid support of Example 5 was used for synthesis of the same 35-residue oligodeoxyribonucleotide on

the Biosearch 8750 synthesis apparatus. The trityl coupling efficiency for this synthesis is shown in Table V.

5 (l) Use of the Solid Support of Example 6 for Synthesis on the Biosearch Synthesis Apparatus

10 The solid support of Example 6 was used for synthesis of the same 35-residue oligodeoxyribonucleotide on the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency is shown in Table V.

(m) Use of the Solid Support of Example 7 for Synthesis with the Biosearch Synthesis Apparatus

15 The solid support of Example 7 was used for synthesis of the same 35-residue oligodeoxyribonucleotide with the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency is given in Table V.

20 (n) Use of the Solid Support of Example 8 for Synthesis on Biosearch Synthesis Apparatus

25 The solid support of Example 8 was used for synthesis of the same 35-residue oligodeoxyribonucleotide on the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency is given in Table V.

(o) Use of Controlled Pore Glass (500 Å Porosity) (Control) For Synthesis on ABI Synthesis Apparatus

30

As a control, controlled pore glass (500 Å porosity) was used for synthesis of the 35-residue oligodeoxyribonucleotide on the ABI PCR Mate DNA synthesis apparatus.

35

(p) Use of Solid Support of Example 1 for Synthesis with ABI Synthesis Apparatus

5 The solid support of Example 1 was used for synthesis of the same 35-residue oligodeoxyribonucleotide on the ABI PCR Mate DNA synthesis apparatus.

(q) Use of Solid Support of Example 5 for Synthesis with ABI Synthesis Apparatus

10

The solid support of Example 5 was used for synthesis of the same 35-residue oligodeoxyribonucleotide with the ABI PCR Mate DNA synthesis apparatus.

15

Example 12

DNA Synthesis of 51-Mer Using Derivatized Solid Support

20

A 51-residue oligodeoxyribonucleotide, 5'-TCCATGGCAACTGTCAAGGCACTGGCTCGTAGCCTACTGGCTTGACCGTAT-3' (SEQ ID NO: 4), was synthesized using the solid supports described above in various DNA synthesis apparatus.

(a) Synthesis Of Controlled Pore Glass (500 Å Porosity) (Control) With Pharmacia Synthesis Apparatus

25

30

The 51-residue oligodeoxyribonucleotide whose sequence is given above was synthesized with controlled pore glass (500 Å porosity), as a control, with the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency for this synthesis is shown in Table IV.

(b) Use of Solid Support of Example 1 For Synthesis With Pharmacia Synthesis Apparatus

5 The solid support of Example 1, above, was used for synthesis of the 51-residue oligodeoxyribonucleotide described above with the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency for this synthesis is given in Table IV.

10 (c) Use of Solid Support of Example 5 For Synthesis With Pharmacia Synthesis Apparatus

15 The solid support of Example 5 was used for synthesis of the 51-residue oligodeoxyribonucleotide whose sequence is given above with the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency for the synthesis is given in Table IV.

20 (d) Use of Solid Support of Example 8 For Synthesis With Pharmacia Synthesis Apparatus

The solid support of Example 8, above, was used for synthesis of the same 51-residue oligodeoxyribonucleotide with the Pharmacia Gene Assembler DNA synthesis apparatus.

25

(e) Synthesis Of Controlled Pore Glass (500 Å Porosity) (Control) With Biosearch Synthesis Apparatus

30 As a control, controlled pore glass (500 Å porosity) was used for synthesis of the 51-residue oligodeoxyribonucleotide whose sequence was given above with the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency for this synthesis is given in Table V.

(f) Use of Solid Support of Example 1 For Synthesis With
Biosearch Synthesis Apparatus

5 The solid support of Example 1, above, was used for
synthesis of the 51-residue oligodeoxyribonucleotide whose
sequence is given above with the Biosearch 8750 DNA synthesis
apparatus. The trityl coupling efficiency is shown in Table
V.

10 (g) Use of Solid Support of Example 7 For Synthesis With
Biosearch Synthesis Apparatus

15 The solid support of Example 7 was used for
synthesis of the 51-residue oligodeoxyribonucleotide whose
sequence is given above with the Biosearch 8750 DNA synthesis
apparatus. The trityl coupling efficiency is shown in Table
V.

20 (h) Use of Solid Support of Example 8 For Synthesis With
Biosearch Synthesis Apparatus

25 The solid support of Example 8, above, was used for
synthesis of the 51-residue oligodeoxyribonucleotide whose
sequence is given above on the Biosearch 8750 DNA synthesis
apparatus. The trityl coupling efficiency for this synthesis
is given in Table V.

30 (i) Use of Solid Support of Example 8 For Synthesis With
Biosearch Synthesis Apparatus

The solid support of Example 8, above, was used for
synthesis of the 51-residue oligodeoxyribonucleotide whose
sequence is given above on the Biosearch 8750 DNA synthesis

apparatus. The trityl coupling efficiency for this synthesis is given in Table V.

Example 13

5 DNA Synthesis of 70-Mer Using Derivatized Solid Support

A 70-residue oligodeoxyribonucleotide, with the sequence of

5'-GATGCCAGTTCGGTCATCCGATGCTCGGTCACGGAAGTGTCAACGGTACCTACTTGTCG
10 TAACGTAGGAT-3' (SEQ ID NO: 5), was synthesized using the solid supports described above with various DNA synthesis apparatus.

(a) Use Of Controlled Pore Glass (1000 Å Porosity) (Control) With Pharmacia Synthesis Apparatus

15 As a control, the 70-residue oligodeoxyribonucleotide whose sequence is given above was synthesized using controlled pore glass (1000 Å porosity), on the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency for this synthesis is given in
20 Table IV.

(b) Use of Solid Support of Example 1 With Pharmacia Synthesis Apparatus

25 The solid support of Example 1 was used with the Pharmacia Gene Assembler DNA synthesis apparatus for synthesis of the 70-residue oligodeoxyribonucleotide whose sequence is given above. The trityl coupling efficiency for this synthesis is shown in Table IV.

30

(c) Use of Solid Support of Example 5 For Synthesis With Pharmacia Synthesis Apparatus

The solid support of Example 5 was used for synthesis of the 70-residue oligodeoxyribonucleotide whose sequence is given above with the Pharmacia Gene Assembler DNA synthesis apparatus. The trityl coupling efficiency for the synthesis is given in Table IV.

(d) Use of Controlled Pore Glass (1000 Å Porosity) (Control) With Biosearch Synthesis Apparatus

10

As a control, the 70-residue oligodeoxyribonucleotide whose sequence is given above was synthesized using controlled pore glass (1000 Å porosity) with the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency for the synthesis is given in Table V.

15

(e) Use of Solid Support of Example 7 For Synthesis With Biosearch Synthesis Apparatus

20

The solid support of Example 7, above, was used for synthesis of the 70-residue oligodeoxyribonucleotide whose sequence is given above with the Biosearch 8750 DNA synthesis apparatus. The trityl coupling efficiency is shown in Table V.

25

Example 14

DNA Synthesis of 101-Mer Using Derivatized Solid Support

A oligodeoxyribonucleotide of 101 residues, with the sequence of 5' -

30

AACGTCGGTAACGTACACGGTAGCTACGGACACCGTGGCAATACGACAGGTAACCTGTGGAA CGTACACGGAAGAGACTAGGGATGGGAGTACGGATGGGT-3' (SEQ ID NO: 6), was synthesized using various solid supports as described above and various DNA synthesis apparatuses.

(a) Use Of Controlled Pore Glass (1000 Å Porosity) (Control)
With Pharmacia Synthesis Apparatus

5 As a control, the 101-residue
oligodeoxyribonucleotide whose sequence is given above was
synthesized using controlled pore glass (1000 Å porosity),
with the Pharmacia Gene Assembler DNA synthesis apparatus.
The trityl coupling efficiency is shown in Table IV.

10 (b) Synthesis Using Solid Support of Example 1 With Pharmacia
Synthesis Apparatus

15 The 101-residue oligodeoxyribonucleotide whose
sequence is given above was synthesized using the solid
support of Example 1 with the Pharmacia Gene Assembler DNA
synthesis apparatus. The trityl coupling efficiency for this
synthesis is given in Table IV.

20 (c) Synthesis With Solid Support of Example 5 Using Pharmacia
Synthesis Apparatus

25 The 101-residue oligodeoxyribonucleotide whose
sequence is given above was synthesized using the solid
support of Example 5 with the Pharmacia Gene Assembler DNA
synthesis apparatus. The trityl coupling efficiency for the
synthesis is given in Table IV.

(d) Synthesis Using Solid Support of Example 6 with Pharmacia
Synthesis Apparatus

30 The 101-residue oligodeoxyribonucleotide whose
sequence is given above was synthesized using the solid
support of Example 6 with the Pharmacia Gene Assembler DNA
synthesis apparatus.

35

(e) Use of Solid Support of Example 8 With Pharmacia
Synthesis Apparatus

5 The 101-residue oligodeoxyribonucleotide whose
sequence is given above was synthesized using the solid
support of Example 8 with the Pharmacia Gene Assembler DNA
synthesis apparatus.

10 (f) Synthesis With Controlled Pore Glass (1000 Å Porosity)
(Control) With Biosearch Synthesis Apparatus

As a control, the 101-residue
oligodeoxyribonucleotide whose sequence is given above was
synthesized using controlled pore glass (1000 Å porosity) with
15 the Biosearch 8750 DNA synthesis apparatus. The trityl
coupling efficiency is shown in Table V.

20 (g) Synthesis Using Solid Support of Example 7 With Biosearch
Synthesis Apparatus

The 101-residue oligodeoxyribonucleotide whose
sequence is given above was synthesized using the solid
support of Example 7, above, with the Biosearch 8750 DNA
synthesis apparatus. The trityl coupling efficiency for the
25 synthesis is shown in Table V.

Capillary gel electropherograms of the synthesized
DNA of Examples 10(d), 11(c), 11(d), 11(e), 11(i), 11(j) (two
batches), 11(k), 11(l), 11(m), 11(n), 11(o), 11(p), 11(q),
30 12(a), 12(b), 12(c), 12(d), 12(e), 12(f), 12(g), 12(h), 12(i),
13(a), 13(b), 13(c), 13(d), 14(a), 14(b), 14(c), 14(d), and
14(e) indicated that the synthesized DNA was at least of
substantially equivalent purity to that obtained by synthesis

of the same DNA sequence on a controlled pore glass solid support.

Example 15

Polyacrylamide Slab Gel Electrophoresis

5

Polyacrylamide slab gel electrophoresis of the synthesized oligodeoxyribonucleotides was performed according to the following protocol. A 22 cm x 16.5 cm denaturing gel was prepared by adding 107.3 ml of water to a 100 g bottle of premixed acrylamide/methylenebisacrylamide (29:1) to make a 50% stock solution. The following were mixed: (1) 20 ml of the 50% acrylamide stock solution; (2) 22.5 g urea; and (3) 5 ml of 10 x TBE (0.9 mole/l Tris-borate, pH 8.0, 0.02 mole/l EDTA). The volume was brought to 50 ml with water, and the solution was heated and stirred to dissolve the urea. To initiate polymerization, 20 mg of ammonium persulfate and 20 μ l N,N,N,N,-tetramethylethylenediamine (TEMED) was added. The gel was poured into the plates, and allowed to polymerize for 1 hour. The gel was then prerun with 1 x TBE at 20 mA for 1 hour. The appropriate quantity of oligodeoxyribonucleotide (0.2-1 A_{260} unit) was mixed in 10 μ l of water with 10 μ l of 10 mole/l urea. The resulting 20- μ l mixture was loaded onto the gel and run at 28 mA for 2-4 hours, depending on the length of the oligodeoxyribonucleotide. The oligodeoxyribonucleotide bands were visualized by UV shadowing on a thin layer chromatography fluorescent plate or by staining with ethidium bromide, as indicated below. The following slab gels were run:

30

Plate I (Figure 9: samples from Examples 10(a), 10(b), 10(c), 11(a), 11(b), 11(f), 11(o), 11(p), 11(p) (2nd batch), and 11(q)).

Plate II (Figure 10: samples from Examples 11(a), 11(b), 11(c), 11(d), and 11(e)).

5 Plate III (Figure 11: samples from Examples 12(f), 12(g), 11(i), 11(j), 11(j) (2nd batch), 11(j) (3rd batch), and 11(k)).

Plate IV (Figure 12: samples from Examples 14(a), 14(b), 14(c), 13(a), 13(b), 13(c), 12(a), 12(b) and 12(c)).

Plate V (Figure 13: samples from Examples 10(a), 10(b), 10(d), 10(c), 11(a), 11(b), 11(d), and 11(c)).

10 Plate VI (Figure 14: samples from Examples 11(a), 11(h), 11(a), and 11(g)).

Plate VII (Figure 15: samples from Examples 11(e), 11(h), 11(i), 11(l), 11(n), 11(i), and 11(n)).

15 Plate VIII (Figure 16: samples from Examples 12(a), 12(e), 12(b), and 12(d)).

Plate IX (Figure 17: samples from Examples 14(a), 14(b), and 14(d)).

Plate X (Figure 18: samples from Examples 14(h), 14(g), 13(e), 13(d), 12(m), 12(i)).

20 Plate X was done with ethidium bromide staining; the others were done with fluorescent visualization.

Example 16

Reverse Phase High Pressure Liquid Chromatography

25 Reverse phase high pressure chromatography separates the desired oligodeoxyribonucleotide, which is expected to carry a lipophilic dimethoxytrityl (DMT group) from failed partial sequences that are not expected to carry the DMT group. The oligodeoxyribonucleotides, cleaved and deprotected
30 from the solid support using ammonia, were directly injected into the HPLC column. The HPLC column used was C₁₈ Ultrasphere (Beckman Instruments, Fullerton, California), 5 μ particles, 4.6 mm x 25 cm. Buffers used were 0.1 mole/l ammonium acetate, pH 6.9 (Buffer A) and acetonitrile (Buffer B). The

elution program, at a flow rate of 1 ml/min, was a gradient to 15% Buffer B from zero time to 20 minutes, a gradient to 25% Buffer B from 20 minutes to 25 minutes, a gradient to 50% Buffer B from 25 minutes to 27 minutes, 50% Buffer B from 27 minutes to 30 minutes, and 0% Buffer B from 30 to 35 minutes.

Samples of synthesis products from the following examples were subjected to reverse phase HPLC: 9(c), 9(d), 9(e); all 24-mers synthesized in Example 10; and 11(a), 11(b), and 11(f).

The HPLC results showed that the nucleotides synthesized were substantially free of partial sequences, confirming the data from capillary gel electrophoresis and trityl coupling efficiency.

Example 17

Composition Analysis of Synthesized Nucleotides By Enzyme Digestion

20

To determine the composition of a number of the synthesized oligodeoxyribonucleotides, they were subjected to enzyme digestion and the products of digestion were separated by HPLC. The two enzymes used were phosphodiesterase I reconstituted with 5 ml of 40 mmole/l Tris, 10 mmole/l MgCl₂, pH 7.5) and alkaline phosphatase from Escherichia coli, at 200 units/1.8 ml. The assay used 0.01 units of phosphodiesterase I and 0.2 units of alkaline phosphatase per assay, which was 25 μ l of phosphodiesterase and 2 μ l of phosphatase per assay. The required quantities of enzyme were added to 1 to 2 A₂₆₀ units of the oligonucleotides. The reactions were incubated at room temperature for 30 minutes to 2 hours. Subsequently, 0.5-1 A₂₆₀ units of the digestion mixture were injected onto a

reverse phase HPLC column. The same column and elution conditions were used as in Example 16.

5 Aliquots of nucleotides synthesized in the following
examples were subjected to composition analysis by enzyme
digestion: 10(a), 10(b), 10(c), 10(d), 11(a), 11(b) (2
batches), 11(c), 11(d), 11(e), 11(f), 11(g), 11(h), 11(i),
11(j), 11(k), 11(l), 11(n), 11(o), 11(p) (2 batches), 11(q),
12(a), 12(b), 12(e), 12(f), 12(g), 13(a), 13(b), 14(a), and
10 14(b). The composition analyses are shown in Tables VII
through IX. The agreements with theoretical composition
values are quite good, especially considering that no
purification was done of the synthesized oligonucleotides
before the compositions were determined.

TABLE VII

COMPOSITION ANALYSIS OF CRUDE OLIGONUCLEOTIDES
SYNTHESIZED ON PHARMACIA GENE ASSEMBLER

Solid Support of Example No.:	Length of DNA Synthesized:									
	24		36		51		70		101	
	Theo./Obs.		Theo./Obs.		Theo./Obs.		Theo./Obs.		Theo./Obs.	
CPG-Thymidine (Control)	A 6	5.97	A 9	13.00	A 10	9.93	A 15	16.32	A 30	32.4
	C 8	7.65	C 9	7.29	C 15	14.1	C 18	15.48	C 20	15.83
	G 5	5.93	G 8	7.23	G 13	12.7	G 19	21.80	G 35	34.58
	T 5	4.45	T 9	7.48	T 13	14.28	T 18	16.38	T 16	18.19
Ex. 1: Fractogel - 65F-1 Thymidine	A 6	6.14	A 9	9.06	A 10	9.90	A 15	15.74	A 30	28.26
	C 8	7.50	C 9	9.39	C 15	14.16	C 18	16.33	C 20	17.79
	G 5	5.88	G 8	7.66	G 13	12.54	G 19	19.49	G 35	36.58
	T 5	4.48	T 9	8.88	T 13	14.40	T 18	18.52	T 16	18.37
Ex. 1 (2nd Batch): Fractogel - 65F-1 Thymidine			A 9	9.26						
			C 9	8.48						
			G 8	8.04						
			T 9	9.21						
Ex. 2: Fractogel - 65F-1 Cytidine			A 9	10.29						
			C 10	9.17						
			G 8	9.17						
			T 8	6.37						
Ex. 3: Fractogel - 65-F-1 Guanosine			A 9	8.52						
			C 9	8.84						
			G 9	9.73						
			T 8	7.90						
Ex. 4: Fractogel - 65-F-1 Adenosine			A 10	11.09						
			C 9	8.28						
			G 8	8.79						
			T 8	6.82						
Ex. 5: Fractogel - 65M Thymidine	A 6	5.58	A 9	9.20						
	C 8	7.84	C 9	8.78						
	G 5	5.9	G 8	8.00						
	T 5	4.69	T 9	9.02						
Ex. 6: Fractogel - 65F-2	A 6	6.03	A 9	9.32						
	C 8	7.48	C 9	8.11						
	G 5	5.85	G 8	9.33						
	T 5	4.64	T 9	8.24						
Ex. 8: Fractogel - 65F-3 Thymidine			A 9	9.14	A 10	10.57				
			C 9	8.25	C 15	13.92				
			G 8	8.34	G 13	15.46				
			T 9	9.26	T 13	11.06				

TABLE VIII

COMPOSITION ANALYSIS OF CRUDE OLIGONUCLEOTIDES
SYNTHESIZED ON BIOSEARCH 8750

Solid Support of Example No.:	Length of DNA Synthesized			
	35		51	
	Theo.	Obs.	Theo.	Obs.
CPG - Thymidine (Control)	A 9	8.98	A 10	9.16
	C 9	8.59	C 15	13.04
	G 8	8.21	G 13	14.8
	T 9	9.21	T 13	13.99
Ex. 1: Fractogel - 65F -1 Thymidine	A 9	8.8	A 10	9.42
	C 9	9.011	C 15	14.00
	G 8	8.01	G 13	12.71
	T 9	9.26	T 13	14.87
Ex. 1 (2nd Batch): Fractogel - 65F-1 Thymidine	A 9	8.55		
	C 9	8.50		
	G 8	9.47		
	T 9	8.47		
Ex. 5: Fractogel - 65M Thymidine	A 9	9.47		
	C 9	7.38		
	G 8	9.83		
	T 9	8.32		
Ex. 6: Fractogel - 65F-2 Thymidine	A 9	9.02		
	C 9	8.23		
	G 8	9.14		
	T 9	8.51		
Ex. 8: Fractogel - 65F-3 Thymidine	A 9	9.18		
	C 9	8.60		
	G 8	7.76		
	T 9	9.46		

TABLE IX

COMPOSITION ANALYSIS OF CRUDE OLIGONUCLEOTIDES
SYNTHESIZED ON ABI PCR MATE

Solid Support of Example No.:	DNA Synthesized (35 Bases)	
	Theoretical	Observed
CPG - Thymidine (Control)	A 6	9.23
	C 9	8.16
	G 8	9.61
	T 9	8.00
Ex. 1: Fractogel - 65F-1 Thymidine	A 9	9.62
	C 9	8.00
	G 8	10.03
	T 9	7.35
Ex. 1 (2nd Batch): Fractogel - 65F-1 Thymidine	A 9	9.13
	C 9	7.94
	G 8	9.88
	T 9	8.04
Ex. 5: Fractogel - 65M Thymidine	A 9	8.69
	C 9	8.40
	G 8	9.77
	T 8	8.14

Example 18Polymerase Chain Reaction (PCR)

The polymerase chain reaction (PCR) was run with the template M13mp18 RF I DNA (New England Biolabs, Beverly, Mass.) using an 18-mer and a 22-mer as primer. The sequences were 5'-CGCCAGGGTTTTCCTCAGT-3' (SEQ ID NO: 7) for the 18-mer and 5'-TTCTGGCGTACCGTTCCTGTCT-3' (SEQ ID NO: 8) for the 22-mer. These primers were synthesized on controlled pore glass supports and on the support of Example 1 and were purified before use by Sep Pak™ cartridge (Waters Chromatography Division of Millipore, Milford, Mass.). The PCR was performed according to the published instructions for the Perkin-Elmer-Cetus amplification reagent kit (Perkin-Elmer-Cetus, Norwalk, Connecticut). Initial melting was at 95°C for 7 minutes, and 25 cycles were then run on the DNA thermal cycler with the following cycle profile: segment 1, 94°C for 1 second; segment 2, 94°C for 1 minute; segment 3, 37°C for 1 second; segment 4, 37°C for 2 minutes; segment 5, 72°C for 1 second; and segment 6, 72°C for 3 minutes. The 957 base pair PCR products were electrophoresed on a 1% agarose gel in TAE (0.04 mole/l Tris-acetate, 0.001 mole/l EDTA), and stained with ethidium bromide, as shown in Figure 19. In Figure 19 lane 1 is the product from the CPG-synthesized primers, lanes 2 and 3 are the products from the primers synthesized by the solid support of Example 1, lane 4 is a gel marker consisting of bacteriophage λ DNA digested with the restriction endonuclease Hind III, showing 2322 and 2027 base pair markers, and lane 5 is a gel marker consisting of plasma pBR 322 DNA digested with the restriction endonuclease Hinf I, showing 1632 and 506 base pair markers. The PCR products from the oligonucleotides synthesized on the solid support of Example 1 were substantially identical to those obtained with the oligonucleotides synthesized on controlled pore glass.

35

Example 19DNA Sequencing

DNA sequencing was performed using the same purified
5 18-mer primer synthesized in Example 18. The template was
M13mp18 single-stranded DNA (New England Biolabs). The
published protocol using α -[35 S]-dATP was followed for chain-
termination sequencing using the Sequenase™ enzyme (United
States Biochemical, Cleveland, Ohio). The nucleotides
10 synthesized using the primers originally synthesized with
controlled pore glass and the solid support of Example 1 were
compared by gel electrophoresis (Figure 20). The results were
substantially identical.

15

Example 205'-Kinase Reaction

A 22-mer as synthesized in Example 18 for the
polymerase chain reaction on controlled pore glass and the
solid support of Example 1 were purified by Sep Pak (Waters
20 Chromatography Division of Millipore, Milford, Mass.) C₁₈
cartridge before the kinase reaction by diluting the
oligonucleotide 1:2 into 0.5 mole/l ammonium acetate, loading
it onto the cartridge, washing the cartridge with water,
diluting the oligonucleotide with 60% methanol in water, and
25 evaporating the methanol:water solvent. The oligonucleotides
were then resuspended in water to a concentration of 1 μ g/ μ l.

For the kinasing procedure, 10 μ of the
oligonucleotide was mixed with 10 μ l of 10 x kinase buffer
30 (0.5 mole/l Tris-HCl, pH 7.6, 0.1 mmole/l MgCl₂, 50 mmole/l
dithiothreitol, and 1 mmole/l EDTA), 10 μ l of ATP (10 mmole/l),
and 30 units T4 polynucleotide kinase (Boehringer Mannheim,
Mannheim, Germany) and the volume was brought to 100 μ l with
water. The reaction mixtures were incubated at 37°C for 45

minutes, then heated at 75°C for 5 to 10 minutes to inactivate the enzymes. The reaction mixtures were analyzed by capillary gel electrophoresis as described above with injection for 10 seconds at 10 kV and separate at 11 kV for 45 minutes at 20°C.

5 The phosphorylated oligonucleotides were differentiated from non-phosphorylated oligonucleotides by spiking the kinase reaction mix 1:2 with 50 µg oligonucleotides and analyzed on capillary gel electrophoresis in the same manner. Both the oligonucleotides synthesized on the solid support of Example 1

10 and the controlled pore glass were phosphorylated at the 5'-ends quantitatively.

Example 21

3'-Terminal Transferase Extension

15

To determine the availability of the 3'-ends of the oligodeoxyribonucleotides for extension by transferase, transferase reactions were performed. The following were mixed: 2.5 A₂₆₀ of the oligonucleotide in 150 µl water, 5 mg TTP

20 (Sigma Chemical Company, St. Louis, Missouri), 5 µl terminal deoxynucleotidyl transferase (15 units/µl) (Bethesda Research Labs, Bethesda, Maryland), and 50 µl tailing buffer (Bethesda Research Labs). The reactions were incubated overnight at 37°C. The reacted nucleotides were purified by Sep Pak C¹⁸

25 cartridge by diluting the reaction mixture 1:2 in 0.5 mmole/l ammonium acetate, loading on the cartridge, washing the cartridge with water, and eluting the oligonucleotides with 60% methanol in water. The eluted oligonucleotides were analyzed by capillary gel electrophoresis in the same manner

30 as described above. Both the oligonucleotides synthesized on the controlled pore glass and on the solid support of Example 1 were substantially quantitatively extended at the 3'-end by the terminal transferase.

Although the present invention has been described in considerable detail with regard to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the
5 descriptions of the preferred versions contained herein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Reddy, Parameswara M
Michael, Maged A

(ii) TITLE OF INVENTION: Derivatized Organic Solid Support for
Nucleic Acid Synthesis

(iii) NUMBER OF SEQUENCES: 8

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Beckman Instruments, Inc.
(B) STREET: 2500 Harbor Boulevard
(C) CITY: Fullerton
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 92634

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/____, ____
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Henry, Janis C.

(B) REGISTRATION NUMBER: 34,347

(C) REFERENCE/DOCKET NUMBER: 134D-1208/PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (714) 773-6971

(B) TELEFAX: (714) 773-7936

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGTAAATGCC ATCGACT

17

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATTGAGAAAG CGCCACGCTT CCCT

24

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GATGCCAGTT CGGTCATACA CGTAGTACTA CGACT

35

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCCATGGCAA CTGTCAAGGC ACTGGCTCGT AGCCTACTGG CTTGACCGTA T

51

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GATGCCAGTT CGGTCATCCG ATGCTCGGTC ACGGAACTGT CAACGGTACC TACTTGTCGT 60

AACGTAGGAT

70

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AACGTCGGTA ACGTACACGG TAGCTACGGA CACCGTGGCA ATACGACAGG TAACCTGTGG 60

AACGTACACG GAAGAGACTA GGGATGGGAG TACGGATGGG T 101

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGCCAGGGTT TTCCAGT

18

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTCTGGCGTA CCGTTCCTGT CT

22

What is claimed is:

1. A solid-phase nucleotide synthesis intermediate comprising:

- 5 (a) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties;
- (b) a nucleoside; and
- 10 (c) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer.

15 2. The intermediate of claim 1 wherein the linker spaces the nucleoside from the polymer by about 6 atoms to about 36 atoms.

20 3. The intermediate of claim 1 wherein the linker comprises at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total

25 chain length of from about 6 to about 36 atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups.

30

4. The intermediate of claim 1 wherein the porous polymer is substantially free from pyranose or furanose moieties or derivatives of pyranose or furanose. moieties.

5. The intermediate of claim 1 wherein the nucleoside is a protected deoxyribonucleoside.

6. The intermediate of claim 5 wherein the
5 protected deoxyribonucleoside is protected at its 5'-end.

7. The intermediate of claim 6 wherein the 5'-protected deoxyribonucleotide is an aryl ester.

8. The intermediate of claim 5 wherein the
10 protected deoxyribonucleoside is protected at its 3'-end.

9. The intermediate of claim 1 wherein the nucleoside is a protected ribonucleoside.
15

10. The intermediate of claim 9 wherein the protected ribonucleoside is protected at its 5'-end.

11. The intermediate of claim 9 wherein the
20 protected ribonucleoside is protected at its 3'-end.

12. A solid-phase nucleotide synthesis intermediate comprising:

(a) a porous solid-phase particulate support
25 comprising a porous organic polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties;

(b) a linear polymer having first and second ends,
30 the linear polymer being covalently linked through the first end to the particulate support, the linear polymer comprising at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group

consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total chain length of from about 3 to about 36 carbon atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups, the linear polymer having an amino group at its second end available for reaction with an activated protected deoxyribonucleoside, the linkage between the particulate support and the first end of the linear polymer comprising a carbamate moiety; and

(c) a nucleoside linked to the second end of the linear polymer.

13. The intermediate of claim 12 wherein the nucleoside is an activated 5'-protected deoxyribonucleoside, the activated protected deoxyribonucleoside comprising an aryl ester, and wherein the carboxyl function of the aryl ester is linked in amide linkage to the amino group at the second end of the linear polymer.

14. The intermediate of claim 12 wherein the porous organic polymer comprises a methacrylate-vinylidene copolymer.

15. The intermediate of claim 12 wherein the linear polymer comprises only one aliphatic diamine.

16. The intermediate of claim 12 wherein the linear polymer comprises only two aliphatic diamines.

17. The intermediate of claim 12 wherein the linear polymer comprises only three aliphatic diamines.

18. The intermediate of claim 15 wherein the aliphatic diamine has a chain length of 6 carbons.

5 19. The intermediate of claim 15 wherein the aliphatic diamine has a chain length of 12 carbons.

20. The intermediate of claim 16 wherein each aliphatic diamine has a chain length of 6 carbons.

10 21. The intermediate of claim 17 wherein each aliphatic diamine has a chain length of 6 carbons.

22. A solid-phase nucleotide synthesis intermediate comprising:

15 (a) a porous solid-phase particulate support comprising a methacrylate-vinylidene copolymer;

(b) a polyethylene glycol linker having from about 2 to about 20 ethylene glycol moieties and having a first end and a second end, the first end covalently attached to the particulate support, the second end terminating in an amine moiety; and

20

(c) a nucleoside linked to the amine moiety at the second end of the polyethylene glycol linker by an amide linkage between the amine moiety and a carboxyl group in covalent linkage with the nucleoside.

25

23. The intermediate of claim 22 wherein the polyethylene glycol linker has from about 4 to about 7 ethylene glycol moieties.

30

24. The intermediate of claim 22 wherein the mean diameter of the particles of the porous particulate support is from about 30 microns to about 70 microns.

25. The intermediate of claim 22 wherein the nucleoside is a protected deoxyribonucleoside.

26. The intermediate of claim 25 wherein the protected nucleoside is protected at its 5'-end.

27. A solid-phase nucleotide synthesis intermediate comprising:

- (a) a porous solid-phase particulate support comprising a porous organic polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties;
- (b) a linear polymer having first and second ends, the linear polymer being covalently linked through the first end to the particulate support, the linear polymer comprising at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total chain length of from about 3 to about 36 carbon atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups, the linear polymer having an amino group at its second end available for reaction with a nucleoside, the linkage between the particulate support and the first end of the linear polymer comprising a spacer with the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)-\text{CH}_2-$, with the first amino group of the diamine moiety attached to the particulate support being substituted with an acetyl group; and
- (c) a nucleoside linked to the second end of the linear polymer.

35

28. The intermediate of claim 27 wherein the nucleoside is an activated 5'-protected deoxyribonucleoside, the activated protected deoxyribonucleoside comprising an aryl ester, and wherein the carboxyl function of the aryl ester is
5 linked in amide linkage to the amino group at the second end of the linear polymer.

29. The intermediate of claim 27 wherein the porous organic polymer comprises a methacrylate-vinylidene copolymer.
10

30. A nucleotide synthesis intermediate comprising:

- (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a diaminohexane moiety linked to a hydroxy
15 residue of the copolymer through a carbonyl group bound to the first amino group of the diaminohexane moiety, forming a carbamate linkage; and
- (c) a 5'-protected deoxyribonucleoside linked to the second amino group of the diaminohexane moiety through a
20 succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

31. A nucleotide synthesis intermediate comprising:

- 25 (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a diaminododecane moiety linked to a hydroxy residue of the copolymer through a carbonyl group bound to the first amino group of the diaminododecane moiety, forming a
30 carbamate linkage; and
- (c) a 5'-protected deoxyribonucleoside linked to the second amino group of the diaminododecane moiety through a succinyl group, thereby forming an amide linkage with the

second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

32. A nucleotide synthesis intermediate comprising:
- 5 (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a first diaminohexane moiety linked to a hydroxy residue of the copolymer through a carbonyl group bound to the first amino group of the diaminohexane moiety,
- 10 forming a carbamate linkage;
- (c) a second diaminohexane moiety whose first amino group is linked to the second amino group of the first diaminohexane moiety through a carbonyl group, forming a urea linkage; and
- 15 (d) a 5'-protected deoxyribonucleoside linked to the second amino group of the second diaminohexane moiety through a succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.
- 20
33. A nucleotide synthesis intermediate comprising:
- (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a first diaminohexane moiety linked to a
- 25 hydroxy residue of the copolymer through a carbonyl group bound to the first amino group of the diaminohexane moiety, forming a carbamate linkage;
- (c) a second diaminohexane moiety whose first amino group is linked to the second amino group of the first
- 30 diaminohexane moiety through a carbonyl group, forming a urea linkage;
- (d) a third diaminohexane moiety whose first amino group is linked to the second amino group of the second

diaminohexane moiety through a carbonyl group, forming a urea linkage; and

- 5 (e) a 5'-protected deoxyribonucleoside linked to the second amino group of the third diaminohexane moiety through a succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

34. A nucleotide synthesis intermediate comprising:

- 10 (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a polyethylene glycol linker having from 4 to 7 ethylene glycol moieties and having a first end and a second end, the first end covalently attached to the copolymer, the
15 second end terminating in an amine moiety; and
- (c) a 5'-protected deoxyribonucleoside linked to the amine moiety of the polyethylene glycol linker through a succinyl group, thereby forming an amide linkage with the amine moiety and an ester linkage between the succinyl group
20 and the protected deoxyribonucleoside.

35. A nucleotide synthesis intermediate comprising:

- (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- 25 (b) a diaminododecane moiety whose first amino group is linked to a hydroxy residue of the copolymer through a spacer with the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)-\text{CH}_2-$, with the first amino group of the diaminododecane moiety being substituted with an acetyl group; and
- 30 (c) a 5'-protected deoxyribonucleoside linked to the second amino group of the diaminododecane moiety through a succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

35

36. A process for producing a particulate porous solid-phase support derivatized with a nucleoside, comprising:

(a) coupling:

5 (i) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties, with:

(ii) a linker having a first and a second end, the first end being covalently attached to the particulate support; and

10 (b) coupling the second end of the linker to a nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer.

37. The process of claim 36 wherein the linker
15 spaces the nucleoside from the polymer by about 6 atoms to about 36 atoms.

38. The process of claim 36 wherein the linker
20 comprises at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total
25 chain length of from about 6 to about 36 atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups.

30 39. A process for producing a particulate porous solid-phase support derivatized with a nucleoside, comprising the steps of:

(a) coupling:

- (i) a porous solid-phase particulate support comprising a porous polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or methacrylate moieties, the porous polymer being extended with a linear polymer having first and second ends, the linear polymer being covalently linked through the first end to the porous polymer, the linear polymer comprising at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total chain length of from about 6 to about 36 carbon atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups, the linear polymer having an amino group at its second end, with:
- (ii) a nucleoside, such that the nucleoside is covalently linked to the amino group at the second end of the linear polymer;
- (b) acylating terminal amino groups remaining uncoupled; and
- (c) blocking hydroxy residues on the solid phase support.

40. The process of claim 39 wherein the porous polymer is substantially free of pyranose or furanose moieties or derivatives of pyranose or furanose moieties.

41. The process of claim 39 wherein the porous solid phase support is condensed with only one aliphatic diamine.

42. The process of claim 39 wherein the porous solid phase support is condensed with only two aliphatic diamines.

5 43. The process of claim 39 wherein the porous solid phase support is condensed with only three aliphatic diamines.

10 44. The process of claim 41 wherein the aliphatic diamine has a chain length of 6 carbons.

 45. The process of claim 41 wherein the aliphatic diamine has a chain length of 12 carbons.

15 46. The process of claim 42 wherein each aliphatic diamine has a chain length of 6 carbons.

 47. The process of claim 43 wherein each aliphatic diamine has a chain length of 6 carbons.

20 48. The process of claim 39 wherein the porous polymer is a methacrylate-vinylidene copolymer.

25 49. The process of claim 39 wherein the aliphatic diamine or diamines are straight-chain diamines.

 50. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside, comprising the steps of:

30 (a) coupling:

 (i) a porous solid-phase support comprising a methacrylate-vinylidene copolymer extended with polyethylene glycol, the polyethylene glycol having from about 2 to about 20 ethylene glycol moieties and containing a terminal amino

group, the terminal amino group being available for reaction with a nucleoside, with:

(ii) a nucleoside, such that the nucleoside is covalently linked to the terminal amino group;

5 thereby forming a solid support derivatized with the nucleoside; and

(b) acylating terminal amino groups remaining uncoupled.

10 51. The process of claim 50 wherein the polyethylene glycol has from 4 to 7 ethylene glycol moieties.

52. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside,
15 comprising the steps of:

(a) condensing a porous solid-phase particulate support comprising a porous polymer, at least partially hydrophilic and having hydroxy residues, whose backbone comprises straight-chain optionally substituted acrylate or
20 methacrylate moieties, with epichlorohydrin;

(b) condensing:

(i) the reaction product between the polymer and epichlorohydrin with:

(ii) at least one aliphatic diamine, each
25 aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the
30 aliphatic diamines having a total chain length of from about 6 to about 36 carbon atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups, to form a modified solid phase support containing at least one diamine linked to the

solid support by a spacer with the structure $-O-CH_2-CHOH-CH_2-$, the modified solid phase support having a terminal amino group available for reaction with a nucleoside;

5 (c) reacting the modified solid phase support with a short-chain alkylamine;

(d) coupling the terminal amino group of the solid phase support with a nucleoside, thereby forming the solid support derivatized with the nucleoside; and

10 (e) acetylating terminal amino groups remaining uncoupled.

53. The process of claim 52 wherein the reaction product between the polymer and epichlorohydrin is condensed with only one diamine.

15

54. The process of claim 53 wherein the diamine has a chain length of 12 carbons.

55. The process of claim 53 wherein the polymer is a methacrylate-vinylidene copolymer.

20

56. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside, comprising the steps of:

25

(a) condensing:

(i) a porous solid-phase particulate support comprising a methacrylate-vinylidene copolymer having hydroxy residues, the particles of the porous support having a mean diameter of about 45 microns and having pores of a size that excludes proteins of molecular weight greater than about 5×10^6 ,
30 with:

(ii) one straight-chain aliphatic diamine having a chain length of 12 carbon atoms to form a modified solid-phase support extended by an aliphatic straight-chain

diamine moiety with a terminal amino group available for reaction with a nucleoside;

5 (b) coupling the terminal amino group with a nucleoside through an succinyl ester group coupled to the nucleoside so that the succinyl residue of the succinylated nucleoside is linked in amide linkage to the terminal amino group, thereby forming the solid support derivatized with the nucleoside, the quantity of protected deoxyribonucleoside derivatized per gram of solid-phase support being about 10
10 $\mu\text{mole/g}$ to about 150 $\mu\text{mole/g}$;

(c) acetylating terminal amino groups remaining uncoupled in step (b); and

(d) blocking hydroxy residues on the solid-phase support.

15

57. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 36.

20

58. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 39.

25

59. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 50.

30

60. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 52.

35

61. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 56.


62. A process for synthesizing an oligodeoxyribonucleotide comprising the steps of:

- 5 (a) selecting the solid-phase nucleotide synthesis intermediate of claim 1, the nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;
- (b) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by treating the intermediate with acid to yield a free 5'-OH group;
- 10 (c) coupling the free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage between the 5'-carbon of the deoxyribonucleoside attached to the solid support and the deoxyribonucleoside residue of the phosphoramidite;
- 15 (d) oxidizing the phosphite linkage to a phosphotriester linkage to yield a dinucleotide attached to the solid support;
- (e) acetylating remaining unreacted 5'-OH groups after the coupling steps;
- 20 (f) repeating, for each additional nucleotide residue added to the chain, the steps of: (b) removing the protecting group, (c) coupling the resulting free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage, (d) oxidizing
- 25 the phosphite linkage to a phosphotriester linkage, and (e) acetylating remaining unreacted 5'-OH groups; and
- (g) cleaving the oligodeoxyribonucleotide from the solid support.

30 63. A process for synthesizing an oligodeoxyribonucleotide comprising the steps of:

- (a) selecting the solid-phase nucleotide synthesis intermediate of claim 1, the nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;

- (b) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by treating the intermediate with acid to yield a free 5'-OH group;
- 5 (c) coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside having a protected 5'-OH group in the presence of a coupling agent and catalyst to form a dinucleotide attached to the solid support;
- 10 (d) optionally, acetylating remaining unreacted 5'-OH groups after the coupling steps;
- (e) repeating, for each additional nucleotide residue added to the chain, the steps of (b) removing the protecting group, (c) coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside, and (d) optionally,
- 15 acetylating remaining unreacted 5'-OH groups; and
- (f) cleaving the completed oligodeoxyribonucleotide from the solid support.

*FIG. 1.*





FIG. 2.

FIG. 3.





FIG. 4.

FIG. 5.







FIG. 6.






FIG. 8.




FIG. 9




FIG.10




FIG. 11




FIG.12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG.17




FIG. 18




FIG. 19




FIG. 20



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 21/00, C08F 8/00	A3	(11) International Publication Number: WO 94/01446 (43) International Publication Date: 20 January 1994 (20.01.94)
(21) International Application Number: PCT/US93/06214 (22) International Filing Date: 29 June 1993 (29.06.93) (30) Priority data: 07/910,223 9 July 1992 (09.07.92) US (71) Applicant: BECKMAN INSTRUMENTS, INC. [US/US]; 2500 Harbor Boulevard, Fullerton, CA 92634 (US). (72) Inventors: REDDY, Parameswara, M. ; 219 Valverde Avenue, Brea, CA 92621 (US). MICHAEL, Maged, A. ; 348 Lavender Lane, Placentia, CA 92670 (US). (74) Agent: MAY, William, H.; Beckman Instruments, Inc., 2500 Harbor Boulevard, Fullerton, CA 92634 (US).	(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 3 March 1994 (03.03.94)	
(54) Title: DERIVATIZED ORGANIC SOLID SUPPORT FOR NUCLEIC ACID SYNTHESIS (57) Abstract <p>A solid-phase nucleotide synthesis intermediate useful for chemical synthesis of oligodeoxyribonucleotides and oligoribonucleotides comprises: (1) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties; (2) a nucleoside; and (3) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer. The linker can comprise at least one optionally substituted aliphatic diamine. Alternatively, the linker can comprise a polyethylene glycol moiety. Preferably, the porous polymer is a methacrylate-vinylidene polymer. The solid-phase support thus produced can be used for oligodeoxyribonucleotide synthesis by either the phosphite-triester or the phosphotriester processes.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07H21/00 C08F8/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 07882 (GENTA INCORPORATED) 14 May 1992	1-63
Y	see the whole document	22-29, 34,35, 50-55, 59,60
X	WO,A,92 07864 (GENTA INC.) 14 May 1992 see the whole document	1,62
X	WO,A,85 01051 (MOLECULAR BIOSYSTEMS INC) 14 March 1985 see page 11 - page 15; examples 1,9	1,62,63
X	WO,A,82 03079 (BIORESEARCH INC.) 16 September 1982 see page 7 - page 11; example 2	1,63

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

20 January 1994

Date of mailing of the international search report

27. 01. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Day, G

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 659 774 (WEBB T.R. AND HSU C-P. S.) 21 April 1987 see the whole document ---	1,27-29, 35, 51-55, 60,62,63
Y	TETRAHEDRON vol. 45, no. 9 , 1989 , OXFORD, GB pages 2777 - 2792 KATZHENDLER J. ET AL 'THE EFFECT OF SPACER, LINKAGE AND SOLID SUPPORT ON THE SYNTHESIS OF OLIGONUCLEOTIDES' cited in the application see page 2778 - page 2780 -----	22-29, 34,35, 50-55, 59,60

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/06214

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9207882	14-05-92	AU-A-	8912291	26-05-92
		CA-A-	2094595	27-04-92
		EP-A-	0554407	11-08-93

WO-A-9207864	14-05-92	AU-A-	8875391	26-05-92
		CA-A-	2094803	27-04-92

WO-A-8501051	14-03-85	AU-B-	575586	04-08-88
		AU-A-	3319684	29-03-85
		EP-A,B	0155950	02-10-85
		JP-T-	60502155	12-12-85

WO-A-8203079	16-09-82	AU-A-	8332182	28-09-82
		EP-A-	0073826	16-03-83

US-A-4659774	21-04-87	NONE		



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 21/00, C08F 8/00	A3	(11) International Publication Number: WO 94/01446 (43) International Publication Date: 20 January 1994 (20.01.94)
(21) International Application Number: PCT/US93/06214 (22) International Filing Date: 29 June 1993 (29.06.93) (30) Priority data: 07/910,223 9 July 1992 (09.07.92) US (71) Applicant: BECKMAN INSTRUMENTS, INC. [US/US]; 2500 Harbor Boulevard, Fullerton, CA 92634 (US). (72) Inventors: REDDY, Parameswara, M. ; 219 Valverde Avenue, Brea, CA 92621 (US). MICHAEL, Maged, A. ; 348 Lavender Lane, Placentia, CA 92670 (US). (74) Agent: MAY, William, H.; Beckman Instruments, Inc., 2500 Harbor Boulevard, Fullerton, CA 92634 (US).	(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims and statement.</i> (88) Date of publication of the international search report: 3 March 1994 (03.03.94) Date of publication of the amended claims and statement: 28 April 1994 (28.04.94)	
(54) Title: DERIVATIZED ORGANIC SOLID SUPPORT FOR NUCLEIC ACID SYNTHESIS (57) Abstract A solid-phase nucleotide synthesis intermediate useful for chemical synthesis of oligodeoxyribonucleotides and oligoribonucleotides comprises: (1) a particulate support comprising a porous polymer whose backbone comprises optionally substituted acrylate or methacrylate moieties; (2) a nucleoside; and (3) a linker having a first and a second end, the first end being covalently attached to the particulate support and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer. The linker can comprise at least one optionally substituted aliphatic diamine. Alternatively, the linker can comprise a polyethylene glycol moiety. Preferably, the porous polymer is a methacrylate-vinylidene polymer. The solid-phase support thus produced can be used for oligodeoxyribonucleotide synthesis by either the phosphite-triester or the phosphotriester processes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CJ	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

AMENDED CLAIMS

[received by the International Bureau on 25 February 1994 (25.02.94);
original claims 1, 3, 4, 12, 27, 36, 38, 39 and 52 amended;
original claims 14, 29 and 55 cancelled; remaining claims unchanged (16 pages)]

1. A solid phase nucleotide synthesis intermediate comprising:
 - (a) a particulate support comprising a porous polymer selected from the group consisting of vinylidene hydroxy methacrylate and vinylidene hydroxy acrylate;
 - (b) a nucleoside; and
 - (c) a linker having a first and a second end, the first end being covalently attached to the particular support via the hydroxy functionality and the second end being covalently attached to the nucleoside, the linker spacing the nucleoside at least 3 atoms away from the polymer.
2. The intermediate of claim 1 wherein the linker spaces the nucleoside from the polymer by about 6 atoms to about 36 atoms.
3. The intermediate of claim 1 wherein the linker comprises at least one aliphatic diamine each said aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamine having a total chain length of from about 6 to about 36 atoms.
4. The intermediate of claim 1 wherein the porous polymer is substantially free from pyranose or furanose moieties or derivatives of pyranose or furanose moieties.
5. The intermediate of claim 1 wherein the nucleoside is a protected deoxyribonucleoside.
6. The intermediate of claim 5 wherein the protected deoxyribonucleoside is protected at its 5'-end.

7. The intermediate of claim 6 wherein the 5'-protected deoxyribonucleotide is an aryl ester.

5 8. The intermediate of claim 5 wherein the protected deoxyribonucleoside is protected at its 3'-end.

9. The intermediate of claim 1 wherein the nucleoside is a protected ribonucleoside.

10 10. The intermediate of claim 9 wherein the protected ribonucleoside is protected at its 5'-end.

11. The intermediate of claim 9 wherein the protected ribonucleoside is protected at its 3'-end.

15 12. A solid-phase nucleotide synthesis intermediate comprising:

(a) a porous solid-phase particulate support comprising a porous polymer selected from the group consisting of vinylidene hydroxy acrylate and vinylidene hydroxy methacrylate;

(b) a linker group having first and second ends, the linker group being covalently linked through the first end to the particulate support via said hydroxy, the linker group comprising [at least one] aliphatic diamine said aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total chain length of from about 3 to about 36 carbon atoms, the linker group having an amino group at its second end, the linkage between the particulate support and

the first end of the linker group comprising a carbamate moiety; and

(c) a nucleoside linked to the second end of the linker group.

5

13. The intermediate of claim 12 wherein the nucleoside is an activated 5'-protected deoxyribonucleoside, the activated protected deoxyribonucleoside comprising an aryl ester, and wherein
10 the carboxyl function of the aryl ester is linked in amide linkage to the amino group at the second end of the linear polymer.

14. (cancelled)

15

15. The intermediate of claim 12 wherein the linear polymer comprises only one aliphatic diamine.

20

16. The intermediate of claim 12 wherein the linear polymer comprises only two aliphatic diamines.

17. The intermediate of claim 12 wherein the linear polymer comprises only three aliphatic diamines.

25

18. The intermediate of claim 15 wherein the aliphatic diamine has a chain length of 6 carbons.

19. The intermediate of claim 15 wherein the aliphatic diamine has a chain length of 12 carbons.

30

20. The intermediate of claim 16 wherein each aliphatic diamine has a chain length of 6 carbons.

35

21. The intermediate of claim 17 wherein each aliphatic diamine has a chain length of 6 carbons.

22. A solid-phase nucleotide synthesis intermediate comprising:

(a) a porous solid-phase particulate support comprising a methacrylate-vinylidene copolymer;

5 (b) a polyethylene glycol linker having from about 2 to about 20 ethylene glycol moieties and having a first end and a second end, the first end covalently attached to the particulate support, the second end terminating in an amine moiety; and

10 (c) a nucleoside linked to the amine moiety at the second end of the polyethylene glycol linker by an amide linkage between the amine moiety and a carboxyl group in covalent linkage with the nucleoside.

15 23. The intermediate of claim 22 wherein the polyethylene glycol linker has from about 4 to about 7 ethylene glycol moieties.

20 24. The intermediate of claim 22 wherein the mean diameter of the particles of the porous particulate support is from about 30 microns to about 70 microns.

25 25. The intermediate of claim 22 wherein the nucleoside is a protected deoxyribonucleoside.

26. The intermediate of claim 25 wherein the protected nucleoside is protected at its 5'-end.

30 27. A solid-phase nucleotide synthesis intermediate comprising:

(a) a porous solid-phase particulate support comprising a porous polymer selected from the group consisting of vinylidene hydroxy acrylate and vinylidene hydroxy methacrylate;

(b) a linker group having first and second ends, the linker group being covalently linked through the first end to the particulate support, the linker group comprising at least one aliphatic diamine, said aliphatic
5 diamine optionally containing up to 2 heteroatoms replacing carbon atoms, and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom,
10 the aliphatic diamine having a total chain length of from about 3 to about 36 carbon atoms, the linker group having an amino group at its second end, the linkage between the particulate support and the first end of the linker group comprising a spacer with the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)\text{OCH}_2-$
15 , with the first amino group of the diamine moiety attached to the particulate support being substituted with an acetyl group; and

(c) a nucleoside linked to the second end of the linker group.

20

28. The intermediate of claim 27 wherein the nucleoside is an activated 5'-protected deoxyribonucleoside, the activated protected deoxyribonucleoside comprising an aryl ester, and wherein
25 the carboxyl function of the aryl ester is linked in amide linkage to the amino group at the second end of the linear polymer.

29. (cancelled)

30

30. A nucleotide synthesis intermediate comprising:
(a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
(b) a diamino hexane moiety linked to a hydroxy
35 residue of the copolymer through a carbonyl group bound

to the first amino group of the diaminohexane moiety,
forming a carbamate linkage; and

5 (c) a 5'-protected deoxyribonucleoside linked
to the second amino group of the diaminohexane moiety
through a succinyl group, thereby forming an amide
linkage with the second amino group and an ester linkage
between the succinyl group and the protected
deoxyribonucleoside.

10 31. A nucleotide synthesis intermediate comprising:

(a) a macroreticular methacrylate-vinylidene
copolymer having hydroxy residues;

15 (b) a diaminododecane moiety linked to a
hydroxy residue of the copolymer through a carbonyl group
bound to the first amino group of the diaminohexane
moiety, forming a carbamate linkage; and

20 (c) a 5'-protected deoxyribonucleoside linked
to the second amino group of the diaminododecane moiety
through a succinyl group, thereby forming an amide
linkage with the second amino group and an ester linkage
between the succinyl group and the protected
deoxyribonucleoside.

25 32. A nucleotide synthesis intermediate
comprising:

(a) a macroreticular methacrylate-vinylidene
copolymer having hydroxy residues;

30 (b) a first diaminohexane moiety linked to a
hydroxy residue of the copolymer through a carbonyl group
bound to the first amino group of the diaminohexane
moiety, forming a carbamate linkage;

35 (c) a second diaminohexane moiety whose first
amino group is linked to the second amino group of the
first diaminohexane moiety through a carbonyl group,
forming a urea linkage; and

(d) a 5'-protected deoxyribonucleoside linked to the second amino group of the second diaminohexane moiety through a succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

33. A nucleotide synthesis intermediate comprising:

- (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a first diaminohexane moiety linked to a hydroxy residue of the copolymer through a carbonyl group bound to the first amino group of the diaminohexane moiety, forming a carbamate linkage;
- (c) a second diaminohexane moiety whose first amino group is linked to the second amino group of the first diaminohexane moiety through a carbonyl group, forming a urea linkage;
- (d) a third diaminohexane moiety whose first amino group is linked to the second amino group of the second diaminohexane moiety through a carbonyl group, forming a urea linkage; and
- (e) a 5'-protected deoxyribonucleoside linked to the second amino group of the third diaminohexane moiety through a succinyl group, thereby forming an amide linkage with the second amino group and an ester linkage between the succinyl group and the protected deoxyribonucleoside.

34. A nucleotide synthesis intermediate comprising:

- (a) a macroreticular methacrylate-vinylidene copolymer having hydroxy residues;
- (b) a polyethylene glycol linker having from 4 to 7 ethylene glycol moieties and having a first end and a second end, the first end covalently attached to the

copolymer, the second end terminating in an amine moiety;
and

(c) a 5'-protected deoxyribonucleoside linked
to the amine moiety of the polyethylene glycol linker
5 through a succinyl group, thereby forming an amide
linkage with the amine moiety and an ester linkage
between the succinyl group and the protected
deoxyribonucleoside.

10 35. A nucleotide synthesis intermediate comprising:

(a) a macroreticular methacrylate-vinylidene
copolymer having hydroxy residues;

(b) a diaminododecane moiety whose first amino
group is linked to a hydroxy residue of the copolymer
15 through a spacer with the structure $-\text{CH}_2-\text{CH}(\text{OCOCH}_3)-\text{CH}_2-$,
with the first amino group of the diaminododecane moiety
being substituted with an acetyl group; and

(c) a 5'-protected deoxyribonucleoside linked
to the second amino group of the diaminododecane moiety
20 through a succinyl group, thereby forming an amide
linkage with the second amino group and an ester linkage
between the succinyl group and the protected
deoxyribonucleoside.

25 36. A process for producing a particulate porous
solid-phase support derivatized with a nucleoside,
comprising:

(a) coupling:

(i) a particulate support comprising a porous
30 polymer selected from the group consisting of vinylidene
hydroxy methacrylates and vinylidene hydroxy acrylates,
with:

(ii) a linker having a first and a second end,
the first end being covalently attached to the
35 particulate support through said hydroxy; and

(b) coupling the second end of the linker to a nucleoside, the linker spacing the nucleoside by at least 3 atoms away from the polymer.

5 37. The process of claim 36 wherein the linker spaces the nucleoside from the polymer by about 6 atoms to about 36 atoms.

10 38. The process of claim 36 wherein the linker comprises at least one aliphatic diamine, said aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, and selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal
15 amino group of the diamine by at least one carbon atom, the aliphatic diamine having a total chain length of from about 6 to about 36 carbon atoms.

20 39. A process for producing a particulate porous solid-phase support derivatized with a nucleoside, comprising the steps of:

(a) coupling:

25 (i) a porous solid-phase particulate support comprising a porous polymer selected from the group consisting of vinylidene hydroxy methacrylate and vinylidene hydroxy acrylate, the porous polymer being extended with a polymer having first and second ends, the polymer comprising at least one aliphatic diamine, said aliphatic diamine optionally containing up to 2
30 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamine having a
35 total chain length of from about 6 to about 36 carbon

atoms, the polymer having an amino group at its second end, with:

(ii) a nucleoside, such that the nucleoside is covalently linked to the amino group at the second end of the polymer;

(b) acylating terminal amino groups remaining uncoupled; and

(c) blocking hydroxy residues on the solid phase support.

40. The process of claim 39 wherein the porous polymer is substantially free of pyranose or furanose moieties or derivatives of pyranose or furanose moieties.

41. The process of claim 39 wherein the porous solid phase support is condensed with only one aliphatic diamine.

42. The process of claim 39 wherein the porous solid phase support is condensed with only two aliphatic diamines.

43. The process of claim 39 wherein the porous solid phase support is condensed with only three aliphatic diamines.

44. The process of claim 41 wherein the aliphatic diamine has a chain length of 6 carbons.

45. The process of claim 41 wherein the aliphatic diamine has a chain length of 12 carbons.

46. The process of claim 42 wherein each aliphatic diamine has a chain length of 6 carbons.

47. The process of claim 43 wherein each aliphatic diamine has a chain length of 6 carbons.

48. The process of claim 39 wherein the porous polymer is a methacrylate-vinylidene copolymer.

49. The process of claim 39 wherein the aliphatic diamine or diamines are straight-chain diamines.

50. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside, comprising the steps of:

(a) coupling:

(i) a porous solid-phase support comprising a methacrylate-vinylidene copolymer extended with polyethylene glycol, the polyethylene glycol having from about 2 to about 20 ethylene glycol moieties and containing a terminal amino group, the terminal amino group being available for reaction with a nucleoside, with:

(ii) a nucleoside, such that the nucleoside is covalently linked to the terminal amino group; thereby forming a solid support derivatized with the nucleoside; and

(b) acylating terminal amino groups remaining uncoupled.

51. The process of claim 50 wherein the polyethylene glycol has from 4 to 7 ethylene glycol moieties.

52. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside, comprising the steps of:

(a) condensing a particulate support comprising a porous polymer selected from the group consisting of vinylidene hydroxy methacrylate and vinylidene hydroxy acrylate, with epichlorohydrin;

5

(b) condensing:

(i) the reaction product between the polymer and epichlorohydrin with:

10

(ii) at least one aliphatic diamine, each aliphatic diamine optionally containing up to 2 heteroatoms replacing carbon atoms, the heteroatoms being selected from the group consisting of O and N, the heteroatoms being bonded solely to carbon and being separated from the terminal amino group of the diamine by at least one carbon atom, the aliphatic diamines having a total chain length of from about 6 to about 36 carbon atoms, with the proviso that, if more than one diamine is present in the linker, the diamines are linked to each other by carbonyl groups, to form a modified solid phase support containing at least one diamine linked to the solid support by a spacer with the structure $-O-CH_2-CHOH-CH_2-$, the modified solid phase support having a terminal amino group available for reaction with a nucleoside;

15

20

(c) reacting the modified solid phase support with a short-chain alkylamine;

25

(d) coupling the terminal amino group of the solid phase support with a nucleoside, thereby forming the solid support derivatized with the nucleoside; and

(e) acetylating terminal amino groups remaining uncoupled.

30

53. The process of claim 52 wherein the reaction product between the polymer and epichlorohydrin is condensed with only one diamine.

54. The process of claim 53 wherein the diamine has a chain length of 12 carbons.

55. (cancelled)

5

56. A process for producing a particulate porous organic solid-phase support derivatized with a nucleoside, comprising the steps of:

(a) condensing:

10

(i) a porous solid-phase particulate support comprising a methacrylate-vinylidene copolymer having hydroxy residues, the particles of the porous support having a mean diameter of about 45 microns and having pores of a size that excludes proteins of molecular weight greater than about 5×10^6 , with:

15

(ii) one straight-chain aliphatic diamine having a chain length of 12 carbon atoms to form a modified solid-phase support extended by an aliphatic straight-chain diamine moiety with a terminal amino group available for reaction with a nucleoside;

20

(b) coupling the terminal amino group with a nucleoside through an succinyl ester group coupled to the nucleoside so that the succinyl residue of the succinylated nucleoside is linked in amide linkage to the terminal amino group, thereby forming the solid support derivatized with the nucleoside, the quantity of protected deoxyribonucleoside derivatized per gram of solid-phase support being about 10 $\mu\text{mole/g}$ to about 150 $\mu\text{mole/g}$;

25

(c) acetylating terminal amino groups remaining uncoupled in step (b); and

30

(d) blocking hydroxy residues on the solid-phase support.

57. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 36.

5 58. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 39.

10 59. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 50.

15 60. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 52.

20 61. A porous solid-phase support derivatized with a protected deoxyribonucleoside produced by the process of claim 56.

62. A process for synthesizing an oligodeoxyribonucleotide comprising the steps of:

25 (a) selecting the solid-phase nucleotide synthesis intermediate of claim 1, the nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;

30 (b) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by treating the intermediate with acid to yield a free 5'-OH group;

(c) coupling the free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage between the 5'-carbon of the deoxyribonucleoside attached to the

solid support and the deoxyribonucleoside residue of the phosphoramidite;

(d) oxidizing the phosphite linkage to a phosphotriester linkage to yield a dinucleotide attached to the solid support;

(e) acetylating remaining unreacted 5'-OH groups after the coupling steps;

(f) repeating, for each additional nucleotide residue added to the chain, the steps of: (b) removing the protecting group, (c) coupling the resulting free 5'-OH group with a deoxyribonucleoside 3'-phosphoramidite having a 5'-protected hydroxyl to form a phosphite linkage, (d) oxidizing the phosphite linkage to a phosphotriester linkage, and (e) acetylating remaining unreacted 5'-OH groups; and

(g) cleaving the oligodeoxyribonucleotide from the solid support.

63. A process for synthesizing an oligodeoxyribonucleotide comprising the steps of:

(a) selecting the solid-phase nucleotide synthesis intermediate of claim 1, the nucleotide synthesis intermediate containing a 5'-protected deoxyribonucleoside;

(b) removing the protecting group of the 5'-protected deoxyribonucleoside attached to the solid support by treating the intermediate with acid to yield a free 5'-OH group;

(c) coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside having a protected 5'-OH group in the presence of a coupling agent and catalyst to form a dinucleotide attached to the solid support;

(d) optionally, acetylating remaining unreacted 5'-OH groups after the coupling steps;

(e) repeating, for each additional nucleotide residue added to the chain, the steps of (b) removing the protecting group, (c) coupling the free 5'-OH group with a 3'-O-phosphorylated deoxyribonucleoside, and (d) optionally, acetylating remaining unreacted 5'-OH groups; and

(f) cleaving the completed oligodeoxyribonucleotide from the solid support.

STATEMENT UNDER ARTICLE 19

Applicant's invention involves the discovery that by utilizing vinylidene hydroxy acrylate or vinylidene hydroxy methacrylate solid support material to synthesize oligonucleotides, unexpectedly high couplings of oligonucleoside to the solid support can be obtained. That is, the efficiencies and yields of the final synthesized oligonucleotide exceed the efficiencies and yields of oligonucleotides using known solid support materials. Thus the novel aspect of this invention is the use of the vinylidene hydroxy methacrylate or vinylidene hydroxy acrylate solid support.

The International Search Report cites references which disclose various solid supports used in oligonucleotide synthesis. None of them, separately or in combination, describe the vinylidene hydroxy methacrylate and vinylidene hydroxy acrylate solid supports which form the basis of Applicant's claimed invention. More particularly, W/O 92/07882 teaches the use of copolymer of a) polyethylenically unsaturated monomers and monoethylenically unsaturated aliphatic monomers and b) polyvinylidene ethylenic monomers and monoethylenically unsaturated monomers. These are hydrophobic monomers having no methacrylate or acrylate or hydroxy functionalities.

Further, W/O 92/07864 mentions derivatized hydroxylated methacrylic polymer beads which are not the vinylidene hydroxy methacrylate or acrylate polymers claimed by Applicant. W/O 85/01051 and W/O 82/03079 describe a list of polymeric support materials on page 11 and page 7, respectively, none of which specifically describe the vinylidene hydroxy methacrylate or acrylate polymers used by Applicant. Similarly, these references do not describe the advantages associated with Applicant's novel use of vinylidene hydroxy methacrylate or acrylate polymers.

Finally U.S. Patent No. 4,659,774 generally describes nucleoside-linker/-polymer-nucleoside composites. This references does not describe Applicant's novel use of vinylidene hydroxy methacrylate or acrylate as a solid support system.

The accompanying Replacement Sheets include claims amended to specify the use of vinylidene hydroxy methacrylate and acrylate solid supports. As described above, this distinction is viewed as novel and inventive over the cited references.

In the discussion above, there is nothing in the cited references which remotely suggest, alone or in combination, the use of vinylidene hydroxy acrylates and methacrylates as a solid support for these syntheses. Indeed, there is nothing in the cited references which even mentions the use of vinylidene hydroxy methacrylates or acrylates as solid supports. Finally, there is no suggestion in the references to combine any of the references, and, even if there was a suggestion, there is nothing in the combination which provides Applicant's claimed invention.